UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

MUTUAL PHARMACEUTICAL COMPANY, INC., *et al.* **Plaintiffs,** **v.** **WATSON PHARMACEUTICALS, INC., *et al.*** **Defendants.**	**Civil Action No. 09-5421(TJB)** **DECLARATION OF JARED M. LINA IN SUPPORT OF DEFENDANT WEST-WARD PHARMACEUTICAL CORP.'S MOTION FOR SUMMARY JUDGMENT**

I, Jared Matthew Lina, declare and state as follows:

1. I am of the age of majority and am competent to give the testimony contained herein.

2. The testimony herein is based upon my own personal knowledge.

3. I am an attorney at the law firm of Arnall Golden Gregory LLP and serve as counsel of record for Defendant West-Ward Pharmaceutical Corp. ("West-Ward") in this lawsuit.

4. The document attached hereto as Exhibit A is a true and correct copy of a letter submitted by Plaintiffs' counsel in this action to United States Magistrate Judge Bongiovanni on or about June 28, 2010 stating that all of the documents produced to Defendants in this lawsuit were produced as they are maintained in the ordinary course of business.

5. The documents attached hereto as Tab 1 are certified copies of the Certificates of Good Standing for Plaintiff Mutual Pharmaceutical Company, Inc., URL Pharma, Inc., United Research Laboratories, Inc., Plaintiff AR Scientific, Inc., and Plaintiff AR Holding Company, Inc.

6. The document attached hereto as Tab 2 is a true and correct copy of a Declaration

executed by Hasmukh Doshi and filed in this lawsuit in Support of Defendants' Joint Opposition to Motion for Preliminary Injunction. A true and correct copy of this Declaration is also available at docket entry number 99.

7. The document attached hereto as Tab 3 is a true and correct copy of a Declaration executed by Andrew Boyer and filed in this lawsuit in Support of Defendants' Joint Opposition to Motion for Preliminary Injunction. A true and correct copy of this Declaration is also available at docket entry number 101.

8. The documents attached hereto as Tabs 4, 5, 7, 8, 10-26, and 36-42 are true and correct copies of documents produced by Plaintiffs Mutual Pharmaceutical Company, Inc., AR Scientific, Inc., and AR Holding Company, Inc. (collectively, "Plaintiffs") in response to discovery requests served in this action pursuant to Fed. R. Civ. P. 34.

9. The document attached hereto as Tab 6 is a true and correct copy of a letter from John Elliott, the Pricing Coordinator for Plaintiff Mutual Pharmaceutical Company, Inc. ("Mutual"), to First Databank dated December 23, 2003, attaching Mutual's package label and product inserts for their unapproved colchicine tablets. This letter was produced by Wolters Kluwer Health, Inc. in response to a subpoena issued and served by Plaintiffs in this action, and was provided to West-Ward by Plaintiffs' counsel.

10. The document attached hereto as Tab 9 is a true and correct copy of a Declaration executed by James D. Berkley and filed in this lawsuit in Support of Defendants' Joint Opposition to Motion for Preliminary Injunction. A true and correct copy of this Declaration is also available at docket entry number 102.

11. The document attached hereto as Tab 27 is a true and correct copy of an article published by *Kaiser Health News* on December 29, 2009 entitled "The High Price of FDA

Approval." I obtained a copy of this letter on July 19, 2010 at http://www.kaiserhealthnews.org/Stories/2009/December/29/FDA-approval.aspx.

12. The document attached hereto as Tab 28 is a true and correct copy of an article published in the *New England Journal of Medicine* on April 14, 2010 entitled "Incentives for Drug Development – The Curious Case of Colchicine." I obtained a copy of this article on July 19, 2010 at http://healthcarereform.nejm.org/?p=3323.

13. The document attached hereto as Tab 29 is a true and correct copy of an article published in *Arthritis Today* on April 20, 2010 entitled "The Price of Gout Drug, Colchicine, Goes Up." I obtained a copy of this article on July 19, 2010 at http://www.arthritistoday.org/news/colchicine-gout-drug-price053.php.

14. The document attached hereto as Tab 30 is a true and correct copy of an article published by the *Wall Street Journal* on April 12, 2010 entitled "An Old Gout Drug Gets New Life and a New Price, Riling Patients." I obtained a copy of this article on July 14, 2010 at http://online.wsj.com/article/SB10001424052748703630404575053303739829726.html.

15. The document attached hereto as Tab 31 is a true and correct copy of an article published by the *Wall Street Journal* on July 7, 2010 entitled "URL Pharma Under Fire for Letters to Docotrs Who Criticize Drug." I obtained a copy of this article on July 14, 2010 at http://online.wsj.com/article/SB10001424052748703615104575329360513759570.html.

16. The document attached hereto as Tab 32 is a true and correct copy of a letter from Stanley Cohen, MD, the President of the American College of Rheumatology, to Janet Woodcock, MD, the Director of the FDA's Center for Drug Evaluation and Research, dated December 18, 2009. I obtained a copy of this letter on July 20, 2010 on Plaintiffs' website at http://www.urlpharma.com/url_unapproved_drug_ACR.aspx.

17. The document attached hereto as Tab 33 is a true and correct copy of a Federal Register notice issued by the United States Food and Drug Administration ("FDA") dated February 8, 2008 entitled "Drug Products Containing Colchicine for Injection; Enforcement Action Dates." I obtained a copy of this Notice on Westlaw at 73 FR 7565, 2008 WL 336641 (F.R. Feb. 8, 2008).

18. The document attached hereto as Tab 34 is a true and correct copy of a document entitled "Questions and Answers about FDA's Enforcement Action Against Unapproved Injectable Colchicine Products" that I obtained from the FDA's website on July 19, 2010 at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm119642.htm.

19. The document attached hereto as Tab 35 is a true and correct copy of a document entitled "Guidance for FDA Staff and Industry: Marketed Unapproved Drugs – Compliance Policy Guide" that I obtained from the FDA's website on July 19, 2010 at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm.

20. The document attached hereto as Tab 43 is a true and correct copy of a letter from the FDA to Sunrise Pharmaceutical, Inc. as such document appeared on the FDA website on July 22, 2010 at http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm197966.htm.

21. The document attached hereto as Tab 44 is a true and correct copy of a letter from the FDA to Vision Pharm, LLC, Inc. as such document appeared on the FDA website on July 22, 2010 at http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm212242.htm.

I declare under penalty of perjury under the laws of the United States that the foregoing is true and correct.

Executed at Atlanta, Georgia on July 22, 2010.



Jared M. Lina

EXHIBIT A

PODVEY MEANOR
CATENACCI HILDNER COCOZIELLO & CHATTMAN

A PROFESSIONAL CORPORATION
COUNSELLORS AT LAW
THE LEGAL CENTER
ONE RIVERFRONT PLAZA SUITE 800
NEWARK, NEW JERSEY 07102-5497
(973) 623-1000 FACSIMILE: (973) 623-9131
www.podvey.com

NEW YORK OFFICE
400 PARK AVENUE SUITE 1420
NEW YORK, NEW YORK 10022
(212) 432-7419
PLEASE REPLY TO NEW JERSEY OFFICE

Via Electronic Mail

June 28, 2010

RE: Mutual Pharmaceutical Company, Inc., et al.
v. Watson Pharmaceuticals, Inc., et. al.
Civil Action No. 09-5421 (GEB)(TJB)
Our File No.: 4041/11349

Honorable Tonianne J. Bongiovanni, U.S.M.J.
United States District Court for the District of New Jersey
Clarkson S. Fisher Federal Building & U.S. Courthouse
402 East State Street, Room 4050
Trenton, New Jersey 08608

Dear Magistrate Judge Bongiovanni:

Plaintiffs Mutual Pharmaceutical Company, Inc. ("Mutual"), AR Scientific, Inc., and AR Holding Company, Inc. (collectively, "Plaintiffs") write to briefly respond to the assertions made in the June 23 letter of Defendant Excellium Pharmaceutical, Inc. ("Excellium") and the June 25 letter of Defendant West-Ward Pharmaceutical Corp. ("West-Ward").

Excellium's June 23 Letter

The sole purpose of Excellium's June 23 letter is to distract the Court's attention from the discovery dispute currently before the Court because Excellium can no longer hide the fact that it has flagrantly disregarded its discovery obligations. The first two pages of Excellium's letter are completely irrelevant to the discovery issues before the Court, since they contain nothing more than a rehashed argument that Plaintiffs' complaint should be dismissed. However, the Court has already denied Defendants' motion to dismiss. Turning back to the issue at hand, Excellium has failed to substantively address nearly all of the issues raised in Plaintiffs' June 17 letter. Therefore, Plaintiffs respectfully request that the Court order Excellium to immediately produce all information and documents responsive to Plaintiffs' discovery requests without further delay.

Plaintiffs sent a letter to Excellium on April 23 that memorialized the representations made by Excellium during the March 31 and April 21 meet and confer meetings and requested that Excellium contact Plaintiffs immediately if it disagreed with anything in the letter (see Exhibit A attached)[1]. Not surprisingly, Excellium never responded to Plaintiffs' April 23 letter. Now that Plaintiffs have sought Court intervention, Excellium belatedly bemoans the fact that Plaintiffs' discovery requests are allegedly overly broad, unduly burdensome, and disconnected from any reasonable approach to the discovery of relevant evidence. As more fully discussed in Plaintiffs' April 23 letter to Excellium and June 17 letter to the Court, Excellium's empty and tardy complaints have no merit and should not be given any weight.

Plaintiffs also feel it is necessary to briefly respond to a few disingenuous points made by Excellium. First, Plaintiffs have fully complied with the parties' agreed upon production protocol by providing all the parties with searchable text, corresponding TIFF images, agreed upon metadata fields, and an associated load file. Notably, Excellium did not provide any substantive input during the negotiation of the production protocol, and never requested any specific form of production or deviation from the agreed upon production protocol. In fact, Excellium did not notify Plaintiffs that it was experiencing any difficulty with the review of the documents produced by Plaintiffs on May 21, until over 3 weeks later. It is also telling that West-Ward and Defendant Vision Pharma LLC ("Vision") have not asserted any difficulties with the review of documents produced by Plaintiffs. Plaintiffs contacted counsel for Excellium on June 15 and June 22 and agreed to try to help Excellium to resolve the technically difficulties that it was experiencing with its document review software, even though Plaintiffs complied with the production protocol and had no obligation to assist Excellium with its IT difficulties. Nevertheless, Plaintiffs' IT team has been working with Excellium's IT team over the last few days and will be providing Excellium with additional information and support today to help rectify the problems with Excellium's document review software.

Second, as set forth in more detail in Plaintiffs' June 17 letter, Plaintiffs gave Excellium every opportunity to resolve this discovery dispute without the need for Court intervention, including two meet and confer meetings and several phone and email conversations with counsel for Excellium. Incredibly, Excellium admits that it did not begin the task of searching for documents and information responsive to Plaintiffs' discovery requests until sometime in May 2010, which is seven months after the discovery requests were served. It is shocking that Excellium complains about the fact that Plaintiffs have "demand[ed] that discovery move rapidly forward", as though a desire to efficiently litigate this matter is undesirable, especially when Excellium has failed to produce any electronically stored information responsive to Plaintiffs' discovery requests and has only produced a total of 167 pages of inappropriately redacted hard copy documents to date.

[1] Although referenced in Plaintiffs' June 17 letter to the Court, Plaintiffs inadvertently neglected to attach Exhibit A. It is attached to this letter for the Court's review.

Third, Excellium's protests regarding the time limitation on Plaintiffs' requests for production can only be explained as posturing to the Court because Excellium specifically agreed to a July 29, 2006 time limitation on all requests for production, unless otherwise specifically limited (see page 2 of Mutual's April 23 letter to Excellium attached as Exhibit A). The production of documents prior to July 29, 2009 is necessary because Plaintiffs are informed and believe that relevant documents related to the marketing, advertising, and promotion of Defendants' unapproved colchicine products were provided by the Defendants to the Price Lists and Wholesalers prior to the FDA-approval of Plaintiffs' COLCRYS colchicine product.

Finally, Excellium's allegation that Plaintiffs have somehow violated their obligations under Rule 11 of the Federal Rules of Civil Procedure is irresponsible. As previously discussed, Defendants filed a motion to dismiss Plaintiffs' complaint, which was denied by this Court. Plaintiffs have clearly met their obligations under Rule 11 and are fully prepared to take this case to a trial on the merits.

West-Ward's June 25 Letter

West-Ward's June 25 letter raises substantive discovery issues unrelated to the issues involving Excellium currently before the Court. Plaintiffs continue to work with West-Ward on a number of discovery disputes between the two parties, including West-Ward's failure to adequately respond to Plaintiffs' discovery requests, and hope to resolve those issues without the need for Court intervention. However, it is important to point out a few of the blatant inconsistencies in West-Ward's letter.

West-Ward contends that Plaintiffs have "consistently frustrated the discovery process," yet West-Ward acknowledges that Plaintiffs have "produced more than 1,800,000 million pages of documents". West-Ward states it is "difficult for Defendants to understand the factual allegations that allegedly support Plaintiffs' claims," while noting that West-Ward has yet to "perform a meaningful review" of the approximately 74,000 responsive documents produced by Plaintiffs to date.

Defendants' complaint about the number of documents produced by Plaintiffs in response to the requests for production of West-Ward, Excellium, and Vision is without merit. Plaintiffs produced documents that Defendants specifically requested, as they are kept in the ordinary course of business, and while preserving all objections to the requests for production. If the Defendants do not wish to spend the time to review the approximately 74,000 documents produced to date, they should not have asked for them in the first place.

With that said, Plaintiffs are reluctantly willing to agree to an extension of the discovery period for sixty days, as the Defendants have requested. Although Plaintiffs are fully prepared to complete their discovery of the relevant facts and issues within the time currently allotted by the

Court, and keep this Action moving along towards a full trial on the merits, Plaintiffs do not wish to waste the parties' or the Court's time arguing about this issue.

Respectfully submitted,

Gregory D. Miller

cc: All Counsel of Record (via Electronic Mail)
Peter J. Willsey, Esq. (via Electronic Mail)
Nishan Kottahachchi, Esq. (via Electronic Mail)

EXHIBIT A

Cooley
GODWARD KRONISH LLP

Nishan Kottahachchi
(202) 842-7886
nkottahachchi@cooley.com

VIA FEDEX AND EMAIL

April 23, 2010

David Novack, Esq.
J. Brooke Hern, Esq.
Budd Larner, P.C.
150 John F. Kennedy Pkwy.
Short Hills, NJ 07078-2703

RE: *Mutual Pharmaceutical Company, Inc., et al. v. Watson Pharmaceuticals, Inc., et al.*
U.S. District Court for the District of New Jersey, Civil Action No. 09-5421 (GEB)(TJB)

Dear David and Brooke:

We write to memorialize Mutual's understanding of the representations made by Excellium Pharmaceutical, Inc. ("Excellium") during our meet and confer meetings of March 31, 2010 and April 21, 2010 regarding the deficient responses served on January 19, 2010 by Excellium to the First Set of Interrogatories, First Set of Requests for Admission, and First Set of Requests for Production of Documents and Things of Plaintiff Mutual Pharmaceutical Company, Inc. ("Mutual"). Please let us know immediately if you disagree with anything in this letter.

As an initial matter, Excellium confirmed that it is no longer withholding any information or documents responsive to Mutual's interrogatories and requests for production based on any objections regarding the production of proprietary and confidential information in light of the Protective Order entered by the Court. We believe that many of the issues raised in our March 15, 2010 letter to Excellium have been addressed by Excellium and we look forward to working with you to resolve the remaining disputes.

Interrogatories

- Interrogatory Nos. 5 and 6 – Excellium agreed to withdraw its objection to these two interrogatories on the grounds that they are premature. Accordingly, Excellium agreed to provide supplemental responses setting forth Excellium's revenues and profits generated by sales of Excellium's colchicine products in the U.S. on a monthly basis from July 30, 2009 to the present.

- Interrogatory Nos. 8 and 9 – Excellium agreed to supplement its responses to these two interrogatories by identifying and describing any instances of consumer confusion known by Excellium regarding (i) the FDA-approval status of Excellium's colchicine products and (ii) whether Excellium's colchicine products can be substituted for Plaintiffs' COLCRYS colchicine product. Excellium agreed that its supplemental responses will be based on the knowledge of the company and not just the specific individuals currently associated with Excellium that are identified in the responses.

- Interrogatory No. 10 – Excellium agreed to withdraw its objection to the terms "detail" and "obtain FDA-approval" as vague and ambiguous. Excellium is maintaining its objection to the term "efforts" on the grounds that Excellium believes the term is vague

and ambiguous. Mutual disagrees that the terms "efforts" is vague and ambiguous since it is a common word that can easily be understood according to its plain meaning. Notwithstanding that objection, Excellium has agreed to supplement its response to this interrogatory to indicate that it has not communicated with the FDA about obtaining FDA-approval for Excellium's colchicine products.

- Interrogatory No. 11 – Excellium agreed to withdraw its objection to the terms "detail" and "means" as vague and ambiguous. Excellium is maintaining its objection to the terms "market" and "advertise" on the grounds that Excellium believes these terms are vague and ambiguous. Mutual disagrees that the terms "market" and "advertise" are vague and ambiguous because they are both common words that can easily be understood according to their plain meaning. Notwithstanding Excellium's objections to those two terms, Excellium has agreed to provide a supplemental, substantive response to this interrogatory.

- Interrogatory Nos. 12 – Excellium refused to provide a supplemental, substantive response to this interrogatory on the grounds that Excellium believes the interrogatory lacks relevance and is not reasonably calculated to lead to admissible evidence. Information concerning the amount of finished colchicine in Excellium's possession, custody, or control is relevant to Mutual's potential damages in this case, and is presumably maintained by Excellium in the ordinary course of business. Accordingly, Mutual reserves its right to seek the Court's intervention to resolve this dispute, but will wait until it has the opportunity to review other damages-related documents and information from Excellium before doing so.

- Interrogatory No. 13 – Mutual withdraws Interrogatory No. 13 concerning the amount of unfinished colchicine in Excellium's possession, custody, or control. Excellium need not provide any supplemental response to this interrogatory.

Requests for Production

- Excellium agreed to withdraw its general objection #10 by which Excellium contended that the production of electronically stored information ("ESI") is premature. The draft production protocol was first circulated on February 18, 2010. Mutual circulated a revised draft production protocol on April 21, 2010 that incorporated comments from West-Ward, Watson, and Vision. We understand that Excellium agreed to the revised April 21 production protocol during a meet and confer meeting held on April 22. Therefore, we expect that Excellium will not delay its efforts to search for, identify, and prepare responsive ESI for production to Mutual.

- Excellium agreed to withdraw general objection #14, which purports to impose a January 1, 2009 time limitation on all the requests for production. As we discussed, Mutual has proposed a July 29, 2006 time limitation (i.e. three years before the FDA-approval of Mutual's COLCRYS colchicine product) to all of the requests (unless otherwise specifically limited) in order to alleviate any potential burden associated with Excellium's efforts to respond to the requests. As agreed by the Parties, one exception to this general time limitation is that there will be no time limitation on the discovery of

Cooley
GODWARD KRONISH LLP

communications between Excellium and Price Lists or Wholesalers regarding Excellium's unapproved colchicine products. Such communications are highly relevant to the claims and defenses asserted in this case regardless of the date of the communications.

- Request Nos. 2, 4, and 6 – Excellium agreed to supplement its response to these three requests and produce any labels, product inserts, and packaging for the colchicine products of (i) the other Defendants in the Action, (ii) Plaintiffs, and (iii) any manufacturers of colchicine products that are not Parties to this Action, which are in Excellium's possession, custody, or control.

- Request No. 7 – Excellium agreed to withdraw its objection to the terms "sale" and "distribution" on the grounds that these terms are vague and ambiguous. However, Excellium has refused withdraw its objections to the terms "advertising," "marketing," and "promotion" as vague and ambiguous. Mutual disagrees that these terms are vague and ambiguous since they are common words that can easily be understood according to their plain meaning. Notwithstanding Excellium's objections to those three terms, Excellium has agreed to supplement its response and produce documents responsive to this request. Excellium further stated that the responsive documents will not be limited to documents that "address the safety, effectiveness, or FDA-approval status of Excellium's colchicine product."

- Request Nos. 9 and 12 – Given the overlap between Request No. 7 and Request Nos. 9 and 12, Mutual is willing to withdraw Request Nos. 9 and 12 provided that Excellium produces all responsive documents concerning Excellium's use of Price Lists and Wholesaler Ordering Systems to advertise, market, promote, sell, or distribute Excellium's colchicine products when responding to Request No. 7.

- Request Nos. 10 and 13 – Given the overlap between Request No. 8 and Request Nos. 10 and 13, Mutual is willing to withdraw Request Nos. 10 and 13 provided that when Excellium responds to Request No. 8, it produces all responsive documents concerning the use of Price Lists and Wholesaler Ordering Systems by parties other than Excellium, i.e. (i) the other Defendants in the Action, (ii) Plaintiffs, and (iii) any manufacturers of colchicine products that are not Parties to this Action, to advertise, market, promote, sell, or distribute their respective colchicine products.

- Request Nos. 11 and 14 – Excellium agreed to supplement its response to these two requests and produce all documents concerning communications between Excellium and Price Lists and Wholesalers regarding Excellium's colchicine products. As noted above and agreed by the Parties, there will be no time limitation on the discovery of communications between Excellium and the Price Lists or Wholesalers regarding Excellium's colchicine products because those communications are highly relevant to the claims and defenses asserted in this case regardless of the date of the communications.

Cooley
GODWARD KRONISH LLP

- Request Nos. 17 and 18 – In discussing Request No. 17 during our initial meet and confer meeting on March 31, you stated that Excellium would let us know if it is withholding any responsive documents concerning FDA-approval of any colchicine products based on any of the objections asserted. During our April 21 meet and confer meeting, you stated that there was no update on this issue. Please let us know whether Excellium is withholding any documents based on any of the objections asserted in the response to Request No. 17, so that Mutual can determine whether it is necessary to seek Court intervention. In discussing Request No. 18 during our initial meet and confer meeting on March 31, you stated that Excellium does not have any documents concerning communications between Excellium and the FDA regarding Excellium's colchicine products because Excellium never sought FDA-approval for its colchicine products. However, you stated that you would confirm this with your client and get back to us. During our April 21 meet and confer meeting, you stated that there was no update on this issue. We look forward to receiving confirmation that Excellium does not have any documents responsive to Request No. 18.

- Request Nos. 20-21 – Excellium agreed to supplement its response to these two requests and produce (i) documents concerning Excellium's revenues, profits, and costs associated with the sale of Excellium's colchicine products since July 2009 and (ii) documents concerning costs Excellium incurred in connection with the manufacturing, advertising, marketing, promotion, sale, or distribution of Excellium's colchicine products since July 2009.

- Request No. 22 – We understand that Excellium is refusing to produce documents in response to this request because Excellium believes documents concerning the amount of Excellium's colchicine products that it purchased, produced, or maintained in its inventory since July 2009 is irrelevant. Documents concerning Excellium's inventory of unapproved colchicine products is relevant to Mutual's potential damages in this action. Accordingly, Mutual reserves its right to seek the Court's intervention to resolve this dispute, but will wait until it has the opportunity to review other damages-related documents and information from Excellium before doing so.

- Request No. 23-25 – Excellium agreed to supplement its response to these three requests and produce documents concerning (i) Excellium's ability to meet market demand for colchicine products in the United States; (ii) Excellium's market share of colchicine products in the United States; and (iii) the market share of colchicine products of any manufacturers other than Excellium in the United States.

- Request Nos. 29-30 – In discussing these two requests during our initial meet and confer meeting on March 31, you indicated that Excellium would let us know whether it intended to produce (i) documents that refer or relate to the existence of a joint defense agreement between the Defendants to cooperate and share in the costs of litigation, including the payment of any damages award granted by the Court to the Plaintiffs in this Action and (ii) documents concerning Excellium's efforts to investigate and cease the acts of false advertising and unfair competition alleged in the complaint in this Action. During our April 21 meet and confer meeting, you stated that there was no update on

Cooley
GODWARD KRONISH LLP

these two requests. Please let us know whether Excellium is withholding any non-privileged documents responsive to these two requests based on any of the objections asserted in the response to Request Nos. 29-30, so that Mutual can determine whether it is necessary to seek Court intervention.

- Request No. 32 – Excellium objected to this request on the grounds that it is irrelevant and unduly burdensome. Mutual disagrees and believes this request is already limited in scope because it only calls for the production of documents regarding communications between Excellium and any of the other Defendants in the Action concerning colchicine products. In addition, this request calls for documents that are clearly relevant and do not fall under the scope of other requests. For example, documents concerning communications between Excellium and any of the Defendants regarding (i) this Action, (ii) any potential resulting liability, or (iii) the FDA-approval status of Plaintiffs' or Defendants' colchicine products are clearly relevant to Mutual's claims and are not duplicative of other requests. Mutual intends to seek Court intervention in order to resolve this dispute.

- Request No. 36 – During our March 31 meet and confer meeting, Excellium requested clarification on the terms "chains" and "independents" as used in this request. The term "chain" refers to chain drug stores such as CVS, Rite Aid, Walgreens, etc. and the term "independents" refers to independent drug stores, including internet drug stores. With that clarification, Mutual expects Excellium to produce all documents responsive to this request, including but not limited to communications pertaining to customer complaints and confusion regarding the safety, efficacy, substitutability, and FDA-approval status of Excellium's colchicine products.

- Request No. 38 - In discussing this request during our initial meet and confer meeting on March 31, you stated that Excellium would let us know whether it intended to produce documents concerning its efforts to secure reimbursement for Excellium's colchicine products by any government insurance program, including but not limited to Medicaid and Medicare. During our April 21 meet and confer meeting, you stated that there was no update on this issue. Discovery on the issue of whether Excellium made any false representations regarding the safety, efficacy, substitutability, and FDA-approval status of Excellium's colchicine product while trying to secure reimbursements for Excellium's unapproved product is clearly relevant to Plaintiffs' claims in this Action. Please let us know whether Excellium is withholding any responsive documents based on any of the objections asserted in the response to this request, so that Mutual can determine whether it is necessary to seek Court intervention.

Requests for Admission

- Request No. 11 – During our March 31 meet and confer meeting, we requested that Excellium confirm that its denial of this request for admission means that Excellium did not make a profit from the sale of its colchicine products after July 30, 2009. During our April 21 meet and confer meeting, you stated that there was no update on this issue. We look forward to receiving confirmation that Excellium did not make any profit from the sale of its colchicine products after July 30, 2009.

Cooley
GODWARD KRONISH LLP

Please confirm that we can expect to receive Excellium's supplemental responses to Interrogatories Nos. 5-6 and 8-11 and supplemental responses to Requests for Production Nos. 2, 4, 6-7, 11, 14, 20-21, and 23-25 by no later than May 7, 2010. Please also let us know when Excellium intends to begin producing documents responsive to Mutual's requests for production.

Please let us know if you believe we have mischaracterized any of the positions taken by Excellium during our meet and confer meetings on March 31 and April 21. Once again, we look forward to working with you to resolve the few remaining disputes between the Parties.

Sincerely,

Nishan Kottahachchi

Nishan Kottahachchi

cc: Peter J. Willsey, Esq.
Brendan J. Hughes, Esq.

TAB 1

COMMONWEALTH OF PENNSYLVANIA

DEPARTMENT OF STATE

JULY 13, 2010

TO ALL WHOM THESE PRESENTS SHALL COME, GREETING:

I DO HEREBY CERTIFY THAT,

MUTUAL PHARMACEUTICAL COMPANY, INC.

is duly incorporated under the laws of the Commonwealth of Pennsylvania and remains a subsisting corporation so far as the records of this office show, as of the date herein.

IN TESTIMONY WHEREOF, I have hereunto set my hand and caused the Seal of the Secretary's Office to be affixed, the day and year above written.

Basil L. Merenda

Acting Secretary of the Commonwealth

Certification Number: 8887606-1
Verify this certificate online at http://www.corporations.state.pa.us/corp/soskb/verify.asp

DSCB:204 (Rev. 81)

ARTICLES OF INCORPORATION

COMMONWEALTH OF PENNSYLVANIA
DEPARTMENT OF STATE – CORPORATION BUREAU
308 NORTH OFFICE BUILDING, HARRISBURG, PA 17120

PLEASE INDICATE (CHECK ONE) TYPE CORPORATION:

- [x] DOMESTIC BUSINESS CORPORATION
- [ ] DOMESTIC BUSINESS CORPORATION A CLOSE CORPORATION – COMPLETE BACK
- [ ] DOMESTIC PROFESSIONAL CORPORATION ENTER BOARD LICENSE NO.

FEE $75.00

010 NAME OF CORPORATION (MUST CONTAIN A CORPORATE INDICATOR UNLESS EXEMPT UNDER 15 P.S. 2908 B)

MUTUAL PHARMACEUTICAL COMPANY, INC.

011 ADDRESS OF REGISTERED OFFICE IN PENNSYLVANIA (P.O. BOX NUMBER NOT ACCEPTABLE)

4629 Adams Avenue

012 CITY	033 COUNTY	013 STATE	064 ZIP CODE
Philadelphia,	Philadelphia (51)	PA	19124

050 EXPLAIN THE PURPOSE OR PURPOSES OF THE CORPORATION

To have unlimited power to engage in and to do any lawful act concerning any or all lawful business for which corporations smay be incorporated under said Business Corporation Law, including, but not limited to, manufacturing, processing, owning, using and dealing in personal property of every class and description, engaging in research and development, furnishing services, and acquiring, owning, using and disposing of real property of any nature whatsoever.

(ATTACH 8½ x 11 SHEET IF NECESSARY)

The Aggregate Number of Shares, Classes of Shares and Par Value of Shares Which the Corporation Shall have Authority to Issue:

040 Number and Class of Shares	041 Stated Par Value Per Share If Any	042 Total Authorized Capital	031 Term of Existence
1,000	$1.00	$1,000.00	Perpetual

The Name and Address of Each Incorporator, and the Number and Class of Shares Subscribed to by each Incorporator

060 Name	061, 062 063, 064 Address (Street, City, State, Zip Code)	Number & Class of Shares
Albert Roberts	4629 Adams Avenue , Philadelphia, PA 19124	500 Common
Theodore Roberts	4629 Adams Avenue, Philadelphia, PA 19124	500 Common
	(ATTACH 8½ x 11 SHEET IF NECESSARY)	

IN TESTIMONY WHEREOF, THE INCORPORATOR (S) HAS (HAVE) SIGNED AND SEALED THE ARTICLES OF INCORPORATION THIS 21 DAY OF September 19 84.

Albert Roberts
Albert Roberts

Theodore H Roberts
Theodore Roberts

– FOR OFFICE USE ONLY –

050 FILED	002 CODE	003 REV BOX	SEQUENTIAL NO.	100 MICROFILM NUMBER
SEP 26 1984			8877	84631954
	REVIEWED BY	004 SICC	AMOUNT	001 CORPORATION NUMBER
	DATE APPROVED		$ 75.00	837247
William R. Davis	DATE REJECTED	CERTIFY TO [ ] REV.	INPUT BY	LOG IN / LOG IN (REFILE)
Secretary of the Commonwealth	MAILED BY DATE	[x] F & I	VERIFIED BY	LOG OUT / LOG OUT (REFILE)

Commonwealth of Pennsylvania

Department of State

S4631955

CERTIFICATE OF INCORPORATION

Office of the Secretary of the Commonwealth

To All to Whom These Presents Shall Come, Greeting:

Whereas, *Under the provisions of the Laws of the Commonwealth, the Secretary of the Commonwealth is authorized and required to issue a "Certificate of Incorporation" evidencing the incorporation of an entity.*

Whereas, *The stipulations and conditions of the Law have been fully complied with by*

MUTUAL PHARMACEUTICAL COMPANY, INC.

Therefore, Know Ye, *That subject to the Constitution of this Commonwealth, and under the authority of the Laws thereof, I do by these presents, which I have caused to be sealed with the Great Seal of the Commonwealth, declare and certify the creation, erection and incorporation of the above in deed and in law by the name chosen hereinbefore specified.*

Such corporation shall have and enjoy and shall be subject to all the powers, duties, requirements, and restrictions, specified and enjoined in and by the applicable laws of this Commonwealth.

Given *under my Hand and the Great Seal of the Commonwealth, at the City of Harrisburg, this* 26th *day of* September *in the year of our Lord one thousand nine hundred and* eighty-four *and of the Commonwealth the two hundred* ninth

William R. Davis

Secretary of the Commonwealth

0837247

INFOSEARCH, INC.
321 N FRONT ST

COMMONWEALTH OF PENNSYLVANIA

DEPARTMENT OF STATE

JULY 13, 2010

TO ALL WHOM THESE PRESENTS SHALL COME, GREETING:

I DO HEREBY CERTIFY THAT,

UNITED RESEARCH LABORATORIES, INC.

is duly incorporated under the laws of the Commonwealth of Pennsylvania and remains a subsisting corporation so far as the records of this office show, as of the date herein.

IN TESTIMONY WHEREOF, I have hereunto set my hand and caused the Seal of the Secretary's Office to be affixed, the day and year above written.

Basil L. Merenda

Acting Secretary of the Commonwealth

Certification Number: 8887607-1
Verify this certificate online at http://www.corporations.state.pa.us/corp/soskb/verify.asp

ARTICLES OF INCORPORATION

1278

TO THE DEPARTMENT OF STATE;
COMMONWEALTH OF PENNSYLVANIA:

In compliance with the requirements of the "BUSINESS CORPORATION LAW," (Act No. 106), approved the 5th day of May, A. D. 1933, the undersigned all of whom are citizens of the United States, desiring that they may be incorporated as a business corporation, do hereby certify:

1st. The name of the corporation is UNITED RESEARCH LABORATORIES, INC.

2nd. The location and post office address of its initial registered office in this Commonwealth is

1135 Callowhill Street, (number) (street) Philadelphia, (city) Philadelphia. (county)

3rd. The purpose or purposes of the corporation are:

To conduct and carry on research in biological chemicals and to manufacture, compound, buy, sell, distribute and deal in chemicals, biological chemicals, pharmaceuticals, drugs and kindred products.

4th. The term of its existence is perpetual.

5th. The authorized capital stock of the corporation is* Five Thousand Dollars ($5.000.00), divided into five hundred (500) shares of the par value of Ten Dollars ($10.00) each.

6th. The amount of paid in capital with which the corporation will begin business is $500.00.

7th. The names and addresses of the first directors and their terms of office are:

Name	Address	Term of Office
Robert Roberts	7060 Forrest Avenue Philadelphia, Pa.	One Year
Albert Roberts	7060 Forrest Avenue Philadelphia, Pa.	One Year
Katherine Roberts	7060 Forrest Avenue Philadelphia, Pa.	One Year

CBC Roll 49-22 FILM 1278

8th. The names and addresses of the incorporators and the number and class of shares subscribed by each are:

Name	Address	No. and Class of Shares
J. Vernon Pimm	926 Land Title Building Philadelphia, Pa.	1
Charles A. Adami	4435 Sherwood Road Philadelphia, Pa.	1
M. Dennis	5211 Baltimore Avenue Philadelphia, Pa.	1

J. Vernon Pimm (SEAL) _____ (SEAL)

Charles A. Adami (SEAL) _____ (SEAL)

M. Dennis (SEAL) _____ (SEAL)

Commonwealth of Pennsylvania
County of Philadelphia } ss:

Before me, a Notary Public in and for the county aforesaid, personally came the above named, J. Vernon Pimm, Charles A. Adami and M. Dennis

who, in due form of law, acknowledged the foregoing instrument to be their act and deed for the purposes therein specified.

Witness my hand and seal of office the 2nd day of October A. D. 1946.

Notary Public
MY COMMISSION EXPIRES JAN. 5, 1947.

(SEAL)

Approved and filed in the Department of State, 11th day of October A. D. 1946

CBC Roll 49-22 Film 1277-1279 Incl.

M 1223

Commonwealth of Pennsylvania

Department of State

To all to whom these Presents shall come, Greeting:

Whereas, In and by the Business Corporation Law (Act No. 106), approved the 5th day of May, Anno Domini, one thousand nine hundred and thirty-three, the Department of State is authorized and required to issue a

CERTIFICATE OF INCORPORATION

evidencing the incorporation of a business corporation organized under the provisions of that law.

And Whereas, The stipulations and conditions of that law have been fully complied with by the persons desiring to incorporate as

UNITED RESEARCH LABORATORIES, INC.

Therefore, Know Ye, That subject to the Constitution of this Commonwealth and, under the authority of the Business Corporation Law, I do by these presents, which I have caused to be sealed with the Great Seal of the Commonwealth, create, erect, and incorporate the incorporators of and the subscribers to the shares of the proposed corporation named above, their associates and successors, and also those who may thereafter become subscribers or holders of the shares of such corporation, into a body politic and corporate in deed and in law by the name chosen and hereinbefore specified, which shall exist

perpetually

and shall be invested with, and have and enjoy all the powers, privileges, and franchises incident to a business corporation and be subject to all the duties, requirements, and restrictions specified and enjoined in and by the Business Corporation Law and all other applicable laws of this Commonwealth.

Given under my Hand and the Great Seal of the Commonwealth, at the City of Harrisburg, this 11th day of October in the year of our Lord one thousand nine hundred and forty-six and of the Commonwealth the one hundred and seventy-first

Secretary of the Commonwealth

Delaware

The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY "URL PHARMA, INC." IS DULY INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE AND IS IN GOOD STANDING AND HAS A LEGAL CORPORATE EXISTENCE SO FAR AS THE RECORDS OF THIS OFFICE SHOW, AS OF THE THIRTEENTH DAY OF JULY, A.D. 2010.

AND I DO HEREBY FURTHER CERTIFY THAT THE SAID "URL PHARMA, INC." WAS INCORPORATED ON THE TWENTIETH DAY OF MAY, A.D. 1997.

AND I DO HEREBY FURTHER CERTIFY THAT THE ANNUAL REPORTS HAVE BEEN FILED TO DATE.

AND I DO HEREBY FURTHER CERTIFY THAT THE FRANCHISE TAXES HAVE BEEN PAID TO DATE.

Jeffrey W. Bullock, Secretary of State

2738299 8300

AUTHENTICATION: 8110095

100738129

DATE: 07-13-10

You may verify this certificate online at corp.delaware.gov/authver.shtml

Delaware

The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY "AR HOLDING COMPANY, INC." IS DULY INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE AND IS IN GOOD STANDING AND HAS A LEGAL CORPORATE EXISTENCE SO FAR AS THE RECORDS OF THIS OFFICE SHOW, AS OF THE THIRTEENTH DAY OF JULY, A.D. 2010.

AND I DO HEREBY FURTHER CERTIFY THAT THE SAID "AR HOLDING COMPANY, INC." WAS INCORPORATED ON THE THIRTIETH DAY OF AUGUST, A.D. 2005.

AND I DO HEREBY FURTHER CERTIFY THAT THE ANNUAL REPORTS HAVE BEEN FILED TO DATE.

AND I DO HEREBY FURTHER CERTIFY THAT THE FRANCHISE TAXES HAVE BEEN PAID TO DATE.



Jeffrey W. Bullock, Secretary of State

4020865 8300

100738129

AUTHENTICATION: 8110093

DATE: 07-13-10

You may verify this certificate online at corp.delaware.gov/authver.shtml

Delaware

The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY "AR SCIENTIFIC, INC." IS DULY INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE AND IS IN GOOD STANDING AND HAS A LEGAL CORPORATE EXISTENCE SO FAR AS THE RECORDS OF THIS OFFICE SHOW, AS OF THE THIRTEENTH DAY OF JULY, A.D. 2010.

AND I DO HEREBY FURTHER CERTIFY THAT THE SAID "AR SCIENTIFIC, INC." WAS INCORPORATED ON THE EIGHTH DAY OF DECEMBER, A.D. 2004.

AND I DO HEREBY FURTHER CERTIFY THAT THE ANNUAL REPORTS HAVE BEEN FILED TO DATE.

AND I DO HEREBY FURTHER CERTIFY THAT THE FRANCHISE TAXES HAVE BEEN PAID TO DATE.

Jeffrey W. Bullock, Secretary of State

3893117 8300

100738129

AUTHENTICATION: 8110094

DATE: 07-13-10

You may verify this certificate online at corp.delaware.gov/authver.shtml

TAB 2

ANTHONY HERMAN (*Pro Hac Vice Pending*)
therman@cov.com
DAMARA L. CHAMBERS (*Pro Hac Vice Pending*)
dchambers@cov.com
COVINGTON & BURLING LLP
1201 Pennsylvania Avenue NW
Washington, D.C. 20004
Telephone: (202) 662-6000
Facsimile: (202) 778-5279

RICHARD A. JONES (Bar No. 135248)
(rjones@cov.com)
COVINGTON & BURLING LLP
One Front Street
San Francisco, CA 94111
Tel: (415) 591-6000
Fax: (415) 591-6091

RICK L. SHACKELFORD (Bar No. 151262)
shackelfordr@gtlaw.com
GREENBERG TRAURIG LLP
2450 Colorado Avenue
Suite 400E
Santa Monica, California 90404
Telephone: (310) 586-3878
Facsimile: (310) 586-7800

Attorneys for Defendant
EXCELLIUM PHARMACEUTICAL, INC.

UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA

MUTUAL PHARMACEUTICAL COMPANY, INC., *et al.*,

Plaintiffs,

v.

WATSON PHARMACEUTICALS, INC., *et al.*,

Defendants.

CASE NO. CV09-05700 PA (RZx)

The Honorable Percy Anderson

DECLARATION OF HASMUKH DOSHI IN SUPPORT OF JOINT OPPOSITION TO MOTION FOR PRELIMINARY INJUNCTION

DECLARATION OF HASMUKH DOSHI

I, HASMUKH DOSHI, hereby declare as follows:

1. I am the President of Excellium, Pharmaceutical, Inc. ("Excellium"). Excellium is a small privately held company that manufactures, markets and distributes pharmaceutical products, including 0.6 mg oral colchicine tablets ("oral colchicine"). Excellium was incorporated in May 1996 and began operating in 1998.

2. In December 1998, Excellium listed its oral colchicine product with the U.S. Food and Drug Administration ("FDA") by submitting a completed Form FDA 2657 Drug Product Listing Form to the FDA. Excellium indicated in blocks 94 to 99 of this form that Excellium did not have a FDA application number for its oral colchicine product. A copy of Excellium's oral colchicine Drug Product Listing Form and the postal receipt from its submission are attached hereto as Exhibit A.

3. Excellium has never stated that oral colchicine is FDA approved. To the contrary, when forms ask for FDA approval information, Excellium writes "none" or a similar response, as it did in the FDA Drug Product Listing form attached hereto as Exhibit A.

4. To my knowledge, Excellium has never received a Warning Letter or other communication from the FDA telling Excellium to stop manufacturing, marketing or distributing oral colchicine.

5. Excellium's first customer for oral colchicine was United Research Laboratories, Inc. ("URL"), which is plaintiffs' pharmaceutical distribution arm. Excellium supplied URL with oral colchicine from January 1999 until January 2006. Over that period, URL purchased approximately 139 million colchicine tablets from Excellium. URL marketed colchicine through drug industry price lists such as *Red Book*. Attached as Exhibit B are copies of the pages on which URL's oral colchicine product appears in the 1998 and 2005 hard copy editions of *Red Book*.

6. Excellium's colchicine product is listed on page 353 of the hardcopy version of the *Red Book*. An explanation for how to read the product listings is provided on page 173. Copies of these pages are attached as Exhibit C to this Declaration. As explained in the "Key to Rx Product Listings" on page 173, in the right hand column of each product entry is a space for the product's Orange Book Code ("OBC"), if the product has one. The "Orange Book" is the common name for the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations, which is a list of drug products that have been approved by the FDA. FDA, Approved Drug Products with Therapeutic Equivalence Evaluations, *available at*: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm ("Orange Book"). Drugs subject to the Drug Efficacy Study Implementation ("DESI") review and pre-1938 drugs are not included in the "Orange Book."

7. On page 353 of the *Red Book*, the OBC column for Excellium's and Vision's oral colchicine product entries is blank, because colchicine is not FDA approved. (Watson's oral colchicine product is not listed in the *Red Book*.) The entries for products on this page that do have FDA approval, however, clearly include a code in the OBC column. An example is colchicine/probenecid, which is

an FDA-approved drug. In the *Red Book*, the two character code in the OBC column clearly identifies colchicine/probenecid's FDA approval.

8. I understand that Plaintiffs have alleged that Excellium misrepresented to First Databank that its oral colchicine product was FDA-approved. Excellium has never communicated to First Databank, or any other drug pricing database provider or wholesaler, that its oral colchicine product is FDA-approved. Excellium registered its oral colchicine product (both the 100 and 1000 count bottle size) with First Databank in 1999 by completing and submitting First Databank's New Product Submission Forms. (Excellium actually made two submissions, because, upon receiving Excellium's first submission, First Databank notified Excellium that there was a new, updated form.) Nowhere on any of the New Product Submission Forms submitted by Excellium is there any mention of FDA approval. Copies of both of the New Product Submission Forms that Excellium provided to First Databank for its oral colchicine product are attached as Exhibit D.

9. Excellium has never told AmerisourceBergen Corporation ("ABC") or any other wholesaler or drug pricing database provider that Excellium's oral colchicine product is the generic equivalent of COLCRYS.

10. Excellium will be severely harmed if the preliminary injunction is granted. If Excellium is enjoined from filling orders for oral colchicine, a drug that has not been removed from the market by the FDA, Excellium's reputation as a reliable and consistent supplier of pharmaceutical products will be damaged. Moreover, the preliminary injunction could damage Excellium's credibility and negatively impact Excellium's entire business.

11. Excellium is a small, closely-held, family-owned business with 47 employees. A preliminary injunction enjoining Excellium from selling oral colchicine could have an enormous impact on the company, potentially resulting in the need for layoffs or even putting Excellium out of business permanently.

12. The requested preliminary injunction would go beyond enjoining Excellium from selling oral colchicine. It would also require Excellium to somehow cause all drug pricing database providers, wholesalers, pharmacies and drug stores to remove Excellium's product information from their computer systems. Identifying all of the computer systems that list information from Excellium's labels and product inserts would be an overwhelming task that, even if possible, would be extremely costly for Excellium.

I declare under penalty of perjury that the foregoing is true and correct.

Executed this 29 day of September, 2009 at Fairfield, New Jersey.

Hasmukh Doshi

Exhibit A

Form Approved: OMB No. 0910-0045. Expiration Date: September 30, 1997. See OMB Statement on Reverse.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

DRUG PRODUCT LISTING

(In accordance with Public Law 92-387)

NAME AND ADDRESS OF FIRM
Excellium Pharmaceutical, Inc.
3-G. Oak Road
Fairfield, NJ. 07004.

COPY

LABELING REVISION
CHANGE OF:
☐ RTE OF A ADMIN ☐ INDICATION
☐ NAME / DOSE / STR / INGR
☐ OTHER (Specify)

FOR FDA USE — CONTROL NO. — RECORD ID

SEC	S	U	PRODUCT TRADE NAME OR CATALOG NAME	NATIONAL DRUG CODE LABELER	NATIONAL DRUG CODE PRODUCT
01			Colchicine	64125	*104

FDA APPLICATION NO.	REPORT DATE MO	DA	YR	TYPE RPT	TYPES OF BUSINESS	PRODUCT TYPE	BIND	LEGAL STATUS	SCHED	PROF USE	PRODUCT DISCONTINUED	BASIS OF CONCENTRATION WHOLE NUMBERS	DECIMAL	UNIT
NDA NE	12	28	98	MD	OTHER (Specify)	H	R				OTHER (Specify)		D6	mG.

DOSAGE FORM	ROUTES OF ADMINISTRATION 1	2	3	OTH	PT	SEC	S	U	SAMPL	PKG CODE	PACKAGE SIZE	PACKAGE TYPE
500	001					03				01100		BOTHD
						03				10100 0		BOTHD
						03						
						03						
						03						

INITIAL MARKETING DATE MO	YEAR	MOST RECENT MARKETING DATE MO	YEAR	DISCONTINUED DATE MO	YEAR
01	1999				

NOTICE: This report is required by law (21 C.F.R. 207.20). Failure to report can result in imprisonment for not more than one year or a fine of not more than $1,000, or both (FD&C Act, Section 303).

SEC	S	U	TYPE	PT	ESTABLISHED NAME OF PRODUCT AND / OR INGREDIENT(S) OR BIOLOGIC PROPER NAME, TEST OBJECTIVE / EQUIPMENT / REAGENT NAME, ETC.	FDA USE ONLY INGREDIENT NO.	AMOUNT WHOLE NUMBER	AMOUNT DECIMAL	UNIT
05			A		colchicine			06	mg
05			I		corn starch				
05			I		Microcrystalline cellulose				
05			I		Lactose Anhydrous				
05			I		Sodium starch Glycolate				
05			I		Sodium Lauryl sulfate				
05			I		Colloidal Silicon Dioxide				
05			I		Magnesium stearate				
05									
05									

SEC	S	U	SITE OR FIRM ESTABLISHMENT REGISTRATION NUMBER	ACTUAL MANUFACTURING SITE OF THE ABOVE DRUG PRODUCT	STATE	FOREIGN COUNTRY	NDC LABELER CODE	SHORT NAME
07			2249201	Excellium Pharmaceutical Inc	NJ		64125	
07								
07								

FORM FDA 2657 (10/94) PREVIOUS EDITION IS OBSOLETE

MAIL
TED STATES POSTAL SERVICE TM

POST OFFICE TO ADDRESSEE EJ519608539US

COPY

Customer Copy

SEE REVERSE SIDE FOR SERVICE GUARANTEE AND INSURANCE COVERAGE LIMITS

IGIN (POSTAL USE ONLY)

ZIP Code 07082	Day of Delivery: ☒ Next ☐ Second	Flat Rate Envelope ☐
e In: 12:00 PM Day: 1 Year: 98	☒ 12 Noon ☐ 3 PM	Postage $ 10.75
e In: 1530 ☐ AM ☒ PM	Military ☐ 2nd Day ☐ 3rd Day	Return Receipt Fee
ght: lbs. 2 ozs. 0	Int'l Alpha Country Code	COD Fee / Insurance Fee
Delivery: ☐ Weekend ☐ Holiday	Acceptance Clerk Initials: TT	Total Postage & Fees $ 10.75

USTOMER USE ONLY

HOD OF PAYMENT:
ess Mail Corporate Acct. No.:
al Agency Acct. No. or al Service Acct. No.:

☐ WAIVER OF SIGNATURE (Domestic Only. Additional merchandise insurance void if waiver of signature is requested.) I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and authorize delivery employee's signature to constitute proof of delivery.
NDELIVERY ☐ Return ☐ Other

FROM: (PLEASE PRINT) PHONE (973) 276-9600
Cerellium Pharmaceutical Inc
3-G Oak Road
Fairfield, NJ 07004

TO: (PLEASE PRINT) PHONE ( )
Food & Drug Administration
CDER/OM/DDM/IMT
7520 Standish Place
Room # 161
Rockville MD. 20855

FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.gov EMS

Label 11-B July 1997

Exhibit B

PROD/MFR	NDC	AWP	DP	OBC
(U.S.)				
(EACH/UNIT)				
6.25 mg/5 ml,				
120 ml, C-V	00556-0343-04	2.50		AA
480 ml, C-V	00556-0343-16	7.10		AA
3840 ml, C-V	00556-0343-28	49.50		AA
(Barre)				
PO, 10 mg-6.25 mg/5 ml,				
118 ml, C-V	55175-1679-06	6.48		EE
[Compumed]				
PO, 10 mg-6.25 mg/5 ml,				
120 ml, C-V	00403-1678-04	3.55		EE
(Generic Generics)				
PO, 10 mg-6.25 mg/5 ml,				
480 ml, C-V	59911-5819-03	7.40		AA
(Goldline)				
PO, 10 mg-6.25 mg/5 ml,				
120 ml, C-V	00904-1510-00	3.83		AA
480 ml, C-V	00904-1510-16	9.75		AA
3840 ml, C-V	00904-1510-28	42.97		AA
(Moore, H.L.)				
SYR, PO, 10 mg-6.25 mg/5 ml,				
120 ml, C-V	00839-7859-65	3.78	2.80	AA
480 ml, C-V	00839-7859-69	9.38	6.95	AA
3840 ml, C-V	00839-7859-78	53.45	39.59	AA
(Morton Grove)				
SYR, PO (RASPBERRY)				
10 mg-6.25 mg/5 ml,				
120 ml, C-V	58432-0686-04	3.88		AA
480 ml, C-V	58432-0686-16	9.90		AA
(PD-RX Pharm)				
SYR, PO, 10 mg-6.25 mg/5 ml,				
240 ml, C-V	55289-0951-08	7.12		EE
(Pharm Assoc)				
SYR, PO, 10 mg-6.25 mg/5 ml,				
5 ml 100s UD, C-V	00121-0547-05	58.76		AA
(Pharmex Pac)				
SYR, PO, 10 mg-6.25 mg/5 ml,				
240 ml, C-V	52959-1419-08	10.95		EE
(Phys Total Care)				
SYR, PO, 10 mg-6.25 mg/5 ml,				
120 ml, C-V	54868-1829-01	5.19		EE
(Qualitest)				
SYR, PO, 10 mg-6.25 mg/5 ml,				
120 ml, C-V	00603-1578-54	8.94		AA
480 ml, C-V	00603-1578-58	10.50		AA
(Rugby)				
SYR, PO, 10 mg-6.25 mg/5 ml,				
480 ml, C-V	00536-7805-85	14.83		AA
3840 ml, C-V	00536-7805-98	50.45		AA
(Schein)				
SYR, PO, 10 mg-6.25 mg/5 ml,				
480 ml, C-V	00364-7390-16	8.45		AA
(Southwood)				
SYR, PO, 10 mg-6.25 mg/5 ml,				
120 ml, C-V	58016-4513-04	7.51		EE
180 ml, C-V	58016-0674-36	8.19		EE
240 ml, C-V	58016-0674-48	10.39		EE
(URL)				
SYR, PO, 10 mg-6.25 mg/5 ml,				
480 ml, C-V	00677-0963-33	10.36		AA
(Wyeth-Ayerst) *See PHENERGAN W/CODEINE*				
(Xactdose)				
SYR, PO (10X10)				
10 mg-6.25 mg/5 ml,				
5 ml 100s UD, C-V	50962-8568-05	60.00	53.22	AA
(Zenith Goldline)				
SYR, PO, 10 mg-6.25 mg/5 ml,				
120 ml, C-V	00182-0348-37	4.38		AA
480 ml, C-V	00182-1712-48	10.84		AA
3840 ml, C-V	00182-1712-41	52.59		AA
CODEINE/PSEUDOEPH				
(Amer Generics) *See NUCODINE*				
(Cypress Pharm) *See CYCOFED*				
(King Pharm) *See KG-FED*				
(Monarch) *See NUCOFED*				
CODEINE/PSEUDOEPH/TRIPROLIDINE				
REPACK				
SYR, PO				
10 mg-30 mg-1.25 mg/5 ml, 480 ml		4.94		
(Alpharma (USPD) *See TRIACIN C*				
(Geneva) *See TRIFED C*				

PROD/MFR	NDC	AWP	DP	OBC
(Major)				
SYR, PO				
10 mg-30 mg-1.25 mg/5 ml,				
480 ml, C-V	00904-1579-16	9.15		AA
3840 ml, C-V	00904-1579-28	67.45		AA
(Moore, H.L.) *See TRIACIN C*				
(Morton Grove)				
SYR, PO (RASPBERRY)				
10 mg-30 mg-1.25 mg/5 ml,				
120 ml, C-V	58432-0462-04	3.40		AA
480 ml, C-V	58432-0462-16	11.79		AA
3840 ml, C-V	58432-0462-28	82.81		AA
(Qualitest) *See TRIPROLIDINE-C*				
(Schein) *See TRIAFED & CODEINE*				
(Southwood)				
SYR, PO				
10 mg-30 mg-1.25 mg/5 ml,				
120 ml, C-V	58016-0459-24	7.20		EE
(Zenith Goldline)				
SYR, PO				
10 mg-30 mg-1.25 mg/5 ml,				
480 ml, C-V	00182-1710-48	11.60		AA
3840 ml, C-V	00182-1710-41	85.10		AA
CODICLEAR DH (Schwarz)				
gg/hydrocodone				
SYR, PO, 100 mg-5 mg/5 ml,				
118.280 ml, C-III	00131-5134-64	16.00		
473.120 ml, C-III	00131-5134-78	55.81		
(Allscripts)				
REPACK				
SYR, PO, 100 mg-5 mg/5 ml,				
120 ml, C-III	54569-3852-00	14.64		
(Compumed)				
REPACK				
SYR, PO, 100 mg-5 mg/5 ml,				
120 ml, C-III	00403-3117-54	11.50		
(PD-RX Pharm)				
REPACK				
SYR, PO, 100 mg-5 mg/5 ml,				
120 ml, C-III	55289-0419-04	19.98		
(Phys Total Care)				
REPACK				
SYR, PO, 100 mg-5 mg/5 ml,				
120 ml, C-III	54868-3104-01	19.91		
CODIMAL DH (Schwarz)				
hydrocodone/phenyleph/pyril				
SYR, PO				
1.66 mg-5 mg-8.33 mg/5ml,				
118.280 ml, C-III	00131-5129-64	11.19		
473.120 ml, C-III	00131-5129-78	37.73		
3784.960 ml, C-III	00131-5129-72	230.83		
(Allscripts)				
REPACK				
SYR, PO				
1.66 mg-5 mg-8.33 mg/5ml,				
120 ml, C-III	54569-3648-00	10.16		
480 ml, C-III	54569-1705-01	29.83		
(Phys Total Care)				
REPACK				
SYR, PO (A.F.)				
1.66 mg-5 mg-8.33 mg/5ml,				
120 ml, C-III	54868-2609-01	11.16		
CODIMAL PH (Schwarz)				
codeine/phenyleph/pyril				
SYR, PO, 10 mg-5 mg-8.33 mg/5 ml,				
118.280 ml, C-V	00131-5038-64	12.55		
473.120 ml, C-V	00131-5038-78	40.71		
3784.960 ml, C-V	00131-5038-72	252.86		
CODIMAL-L.A. (Schwarz)				
cpm/pseudoeph				
CER, PO, 8 mg-120 mg,				
100s ea	00131-4213-37	52.41		
1000s ea	00131-4213-43	472.00		
(Phys Total Care)				
REPACK				
CER, PO, 8 mg-120 mg,				
20s ea	54868-1611-01	9.15		
CODIMAL-L.A. HALF (Schwarz)				
cpm/pseudoeph				
CER, PO, 4 mg-60 mg,				
100s ea	00131-4581-37	37.96		
(Chesbire)				
REPACK				
CER, PO, 4 mg-60 mg,				
14s ea	55175-2418-04	7.98		
20s ea	55175-2418-06	10.49		

PROD/MFR	NDC	AWP	DP	OBC
(Phys Total Care)				
REPACK				
CER, PO, 4 mg-60 mg,				
20s ea	54868-1958-01	7.20		
CODITUSS DH (Qualitest)				
hydrocodone/phenyleph/pyril				
SYR, PO (STRAWBERRY)				
1.66 mg-5 mg-8.33 mg/5ml,				
120 ml, C-III	00603-1111-54	5.60		
480 ml, C-III	00603-1111-58	17.98		
3840 ml, C-III	00603-1111-66	135.40		
(Vintage)				
SYR, PO (STRAWBERRY)				
1.66 mg-5 mg-8.33 mg/5ml,				
118 ml, C-III	00254-9078-53	5.60		
473 ml, C-III	00254-9078-54	17.95		
CODOTUSS (Major)				
gg/hydrocodone				
LIQ, PO (A.F., D.F., S.F.,ORANGE)				
100 mg-5 mg/5 ml,				
480 ml, C-III	00904-7888-16	30.20		
CODRYNE DHC (Forest Pharm)				
SEE SECTION 6 FOR MFG CATALOG				
POW, 5 gm	00452-3656-80	10.25		
25 gm	00452-3656-81	32.80		
100 gm	00452-3656-82	135.00		
(Medisca)				
POW, 5 gm	38779-0127-15	35.50		
25 gm	38779-0127-25	161.50		
100 gm	38779-0127-10	565.95		
(Meridian Chemical)				
POW, 5 gm	62991-1343-01	39.60		
25 gm	62991-1343-02	176.00		
100 gm	62991-1343-03	616.00		
COFATRIN FORT (Ampharm)				
sir2/inp				
TAB, PO, 800 mg-160 mg,				
10s ea	58915-6459-01	3.90		EE
COGENTIN (Merck)				
benztropine mesylate				
SEE SECTION 7 FOR COLOR PHOTO				
INJ, IV (AMP)				
1 mg/ml, 2 ml 6s	00006-3275-16	42.50	34.00	
TAB, PO, 0.5 mg, 100s ea	00006-0021-68	19.04	15.23	AA
1 mg, 100s ea	00006-0635-68	21.75	17.40	AA
2 mg, 100s ea	00006-0050-68	27.44	21.95	AA
(Allscripts)				
REPACK				
TAB, PO, 2 mg, 50s ea	54569-1595-01	12.73		AA
(Phys Total Care)				
REPACK				
INJ, IV (AMP)				
1 mg/ml, 2 ml 6s	54868-2429-01	46.75		
COGNEX (Forte-Davis)				
tacrine hydrochloride				
SEE SECTION 7 FOR COLOR PHOTO				
CAP, PO (10X10)				
10 mg, 100s ea UD	00071-8695-40	130.46		
120s ea (10X10)	00071-8696-25	137.24		
20 mg, 100s ea UD	00071-8697-40	130.46		
120s ea (10X10)	00071-8697-25	137.24		
30 mg, 100s ea UD	00071-8695-40	130.46		
120s ea (10X10)	00071-8695-25	137.24		
40 mg, 100s ea UD	00071-8698-40	130.46		
120s ea	00071-8698-25	137.24		
COLA (Gallipot)				
SYR, 120 ml	51552-0291-04	2.42		
480 ml	51552-0291-16	5.04		
3840 ml	51552-0291-41	16.68		
COLCRYS (A.A Spectrum)				
SEE SECTION 6 FOR MFG CATALOG				
POW, 0.5 gm	00452-7216-01	25		
5 gm	00452-7216-02	143.00		
25 gm	00452-7216-05	715.00		

PROD/MFR	NDC	AWP	DP	DSC
(Abbott Pharm)				
TAB, PO, 0.5 mg, 100s ea	00074-6974-02	29.54	24.87	
0.6 mg, 100s ea	00074-3781-01	22.64	19.06	
(Allscripts)				
TAB, PO, 0.6 mg, 20s ea	54569-0236-02	1.25		
30s ea	54569-0236-06	4.20		
60s ea	54569-0236-03	8.40		
100s ea	54569-0236-05	6.51		
(Bedford)				
INJ, IJ (S.D.V., P.F)				
0.5 mg/ml,				
2 ml 10s	55390-0605-02	50.40		
(Caraganna)				
TAB, PO, 0.6 mg, 6s ea	00403-2445-06	2.65		
10s ea	00403-2445-10	2.45		
20s ea	00403-2445-20	5.40		
100s ea	00403-2445-01	4.95		
(Consolidated Midland)				
TAB, PO, 0.6 mg, 100s ea	59223-0783-01	3.95		
1000s ea	59223-0783-02	19.75		
(Heartland)				
TAB, PO, 0.6 mg, 30s ea UD	61392-0715-30	4.20		
(BLISTER PACK)				
0.6 mg, 30s ea	61392-0715-30	4.20		
31s ea UD	61392-0715-31	4.34		
32s ea UD	61392-0715-32	4.48		
45s ea UD	61392-0715-45	6.30		
60s ea UD	61392-0715-60	8.40		
90s ea UD	61392-0715-90	12.60		
500s ea UD	61392-0715-51	70.00		
2000s ea UD	61392-0715-54	280.00		
10000s ea UD	61392-0715-91	1400.00		
(Major)				
TAB, PO, 0.6 mg, 100s ea	00904-2847-53	4.30		
1000s ea	00904-2847-60	21.40		
(Medisca)				
POW, (U.S.P.)				
1 gm	38779-0487-11	54.90		
5 gm	38779-0487-15	233.00		
(Meridian Chemical)				
POW, 1 gm	62991-1229-02	116.00		
5 gm	62991-1229-03	464.00		
500 gm	62991-1229-01	62.70		
(Moore, H.L.)				
TAB, PO, 0.6 mg, 100s ea	00839-5152-06	6.01	4.45	
1000s ea	00839-5152-16	24.50	18.15	
(PD-Rx Pharm)				
TAB, PO, 0.5 mg, 30s ea	55289-0724-30	13.13		
0.6 mg, 252 ea UD	55289-0156-97	6.13		
(Phys Total Care)				
TAB, PO, 0.5 mg, 100s ea	54868-2258-01	32.20		
0.6 mg, 30s ea	54868-0998-00	2.20		
(Qualitest)				
TAB, PO, 0.6 mg, 100s ea	00603-3852-21	5.52		
1000s ea	00603-3852-32	23.50		
(Quality Care)				
TAB, PO, 0.5 mg, 30s ea	60346-0506-30	23.57		
0.6 mg, 6s ea	60346-0583-06	5.81		
20s ea	60346-0583-20	4.15		
25s ea UD	60346-0583-25	9.60		
30s ea	60346-0583-22	4.22		
90s ea	60346-0583-90	5.81		
(Rexar)				
TAB, PO, 0.6 mg, 1000s ea	00555-1281-10	16.95		
(Rugby)				
TAB, PO, 0.6 mg, 1000s ea	00536-3494-10	169.75		
(Schein)				
TAB, PO, 0.5 mg, 100s ea	00364-0674-01	19.30		
1000s ea	00364-0674-02	173.70		
(Shire Richwood)				
TAB, PO, 0.6 mg, 100s ea	58521-0187-01	5.00		
1000s ea	58521-0187-10	23.60		
(URL)				
TAB, PO, 0.6 mg, 100s ea	00677-0048-01	4.60		
(West-Ward)				
TAB, PO, 0.5 mg, 100s ea	00143-1281-01	7.55		
100s ea UD	00143-1281-25	19.05		
1000s ea	00143-1281-10	32.50		
(Zenith Goldline)				
TAB, PO, 0.6 mg, 1000s ea	00182-0174-10	172.10		

PROD/MFR	NDC	AWP	DP	DSC
COLCHICINE/PROBENECID (Cheshire)				
TAB, PO, 0.5 mg-500 mg,				
30s ea	55175-3942-06	7.25		EE
45s ea	55175-3942-05	9.84		EE
90s ea	55175-3942-09	15.23		EE
(Global Pharm)				
TAB, PO, 0.5 mg-500 mg,				
100s ea	00115-4382-01	14.41		BP
1000s ea	00115-4382-03	110.85		BP
(Major)				
TAB, PO, 0.5 mg-500 mg,				
100s ea	00904-2182-60	16.70		SP
(Phys Total Care)				
TAB, PO, 0.5 mg-500 mg,				
30s ea	54868-2179-01	5.79		EE
60s ea	54868-2179-00	10.24		EE
(Qualitest)				
TAB, PO, 0.5 mg-500 mg,				
100s ea	00603-5382-21	26.48		BP
(Schein)				
TAB, PO, 0.5 mg-500 mg,				
100s ea	00364-0315-01	32.05		SP
(Trexton)				
TAB, PO, 0.5 mg-500 mg,				
1000s ea	00453-5316-10	103.50		EE
(URL)				
TAB, PO, 0.5 mg-500 mg,				
100s ea	00677-0338-01	26.48		SP
(Zenith Goldline)				
TAB, PO, 0.5 mg-500 mg,				
100s ea	00172-2193-60	18.50		BP
1000s ea	00172-2193-10	160.70		BP
COLESTID (Pharmacia/Upjohn)				
colestipol hydrochloride				
GRR, PO, 5 gm/packet,				
30s ea	00009-0258-01	43.99	35.19	
90s ea	00009-0258-04	129.39	103.46	
5 gm/scoopful,				
300 gm	00009-0259-17	55.03	44.02	
500 gm	00009-0259-02	91.71	73.37	
TAB, PO, 1 gm, 120s ea	00009-0456-03	40.63	32.50	
COLESTID FLAVORED (Pharmacia/Upjohn)				
colestipol hydrochloride				
GRR, PO (7.5 GM PACKET)				
5 gm/7.5 gm,				
60s ea	00009-0375-03	86.20	68.96	
450 gm	00009-0375-05	55.03	44.02	
(Phys Total Care)				
[redacted]				
GRR, PO, 5 gm/7.5 gm,				
7.500 gm 30s	54868-3061-00	46.08		
COLESTIPOL HYDROCHLORIDE				
(Pharmacia/Upjohn) *See COLESTID*				
(Pharmacia/Upjohn) *See COLESTID FLAVORED*				
COLFED-A (Eramin)				
cpm/pseudoph				
CER, PO, 8 mg-120 mg,				
100s ea	55053-0740-01	19.95		
500s ea	55053-0740-05	92.55		
(Parmed)				
CER, PO, 8 mg-120 mg,				
100s ea	00349-8782-01	18.03		
COLFOSCERIL PALMITATE				
(Glaxo Wellcome) *See EXOSURF NEONATAL*				
COLIMIST (Clint)				
brompheniramine maleate				
INJ, IJ (VIAL)				
10 mg/ml, 10 ml	55553-0602-10	14.75		
COLIDROPS (A. G. Mario)				
bell alk/phenobarb				
LIQ, PO (DROPS)				
15 ml	12539-0315-15	9.50		
COLISTIMETHATE SODIUM				
(Parke-Davis) *See COLY-MYCIN M*				
COLISTIN SULFATE (Paddock)				
POW, (U.S.P.)				
50 gm	00574-0477-01	397.13		
COLISTIN/HC ACE/NEO SULF/THONZONIUM BRO-MIDE				
(Parke-Davis) *See COLY-MYCIN S OTIC*				
COLLAGEN HEMOSTAT				
(Astra USA) *See HEMOPAD*				
(Astra USA) *See HEMOTENE*				

PROD/MFR	NDC	AWP	DP	DSC
(Genesis Bio-Pharm) *See COLLASTAT*				
(J&J Medical) *See INSTAT COLLAGEN ABSORBABLE HEMOSTAT*				
(J&J Medical) *See INSTAT MCH COLLAGEN HEMOSTAT*				
COLLAGENASE				
(Knoll Labs) *See SANTYL*				
(Medisca)				
POW, 1 gm	38779-0542-11	584.00		
5 gm	38779-0542-15	2336.00		
COLLASTAT (Genesis Bio-Pharm)				
collagen hemostat				
SPG, TP (HEMOSTATIC PAD, 9"X10")				
5s ea	21181-1284-29	1025.00		
(HEMOSTATIC PAD, 1"X 2")				
10s ea	21181-1284-06	185.00		
(HEMOSTATIC PAD, 3"X 4")				
10s ea	21181-1284-10	370.00		
COLLODIAN FLEXIBLE (Gallipot)				
collodion				
LIQ, (U.S.P./N.F.)				
120 ml	51552-0117-04	9.26		
480 ml	51552-0117-16	36.92		
[redacted]				
(Amend)				
LIQ, (U.S.P.)				
120 ml	17317-0128-04	7.00		
500 ml	17317-0128-01	13.65		
4000 ml	17317-0128-05	70.00		
20000 ml	17317-0128-66	340.00		
(Baker, J.T.)				
LIQ, (U.S.P.)				
100 ml	10106-0282-04	23.06		
500 ml	10106-0282-01	19.53		
(GaBipot)				
LIQ, (U.S.P./N.F.)				
100 ml	51552-0283-09	19.32		
480 ml	51552-0283-16	37.66		
(Hanna)				
LIQ, 120 ml	00395-0649-94	7.30		
(Integra)				
LIQ, (U.S.P.)				
100 ml	05324-5096-48	18.15		
500 ml	05324-5096-58	26.88		
4000 ml	05324-5096-65	124.86		
(Mallinckrodt Lab)				
SOL, (U.S.P.)				
120 ml	00406-4560-42	9.76		
(U.S.P., FLEXIBLE)				
150 ml	00406-4560-62	12.42		
(U.S.P.)				
500 ml	00406-4560-20	19.46		
(U.S.P., FLEXIBLE)				
500 ml	00406-4560-64	19.10		
[redacted]				
(Amend)				
LIQ, (U.S.P.)				
120 ml	17317-0129-04	7.00		
500 ml	17317-0129-01	13.65		
4000 ml	17317-0129-05	70.00		
20000 ml	17317-0129-66	340.00		
(Baker, J.T.)				
LIQ, (U.S.P.)				
100 ml	10106-0284-04	23.04		
500 ml	10106-0284-01	17.47		
4000 ml	10106-0284-05	85.06		
(Integra)				
LIQ, (U.S.P.)				
100 ml	05324-5097-48	19.80		
500 ml	05324-5097-58	31.22		
4000 ml	05324-5097-65	127.04		
(Paddock)				
LIQ, (U.S.P.)				
120 ml	00574-0568-04	8.60		
480 ml	00574-0568-16	32.10		

PROD/MFR	NDC	AWP	DP	DESC
(PCCA) *See COCA COLA*				
COLA FLAVOR (PCCA)				
flavoring sol				
SOL, NA (CAFFEINE-FREE)				
1 ml	51927-3414-98	0.30		
COLA NUT				
(PCCA) *See KOLA NUT*				
COLAZAL (Salix Pharm)				
balsalazide disodium				
CAP, PO, 750 mg, 280s ea	65649-0181-02	358.32		
COLCHICINE (Abbott Pharm)				
TAB, PO, 0.6 mg, 100s ea	00074-3787-01	33.08	29.00	
(Alphapan)				
TAB, PO, 0.6 mg, 100s ea	59743-0685-01	23.62		
1000s ea	59743-0685-10	173.91		
(Bedford)				
SOL, IV (S.D.V./PF)				
0.5 mg/ml,				
2 ml 10s	55390-0605-02	74.40		
(Consolidated Midland)				
TAB, PO, 0.6 mg, 100s ea	00223-0703-01	3.95		
1000s ea	00223-0703-02	19.75		
(Excalibur)				
TAB, PO, 0.6 mg, 100s ea	54125-0184-01	26.99		
1000s ea	54125-0184-10	174.99		
(PCCA)				
POW, NA (U.S.P.)				
1 gm	51927-1895-00	204.00		
(Qualitest)				
TAB, PO, 0.6 mg, 100s ea	00603-3052-21	25.98		
1000s ea	00603-3052-32	174.96		
(Spectrum Pharmacy Prod)				
POW, NA (U.S.P.)				
1 gm	49452-2218-02	87.00		
5 gm	49452-2218-05	365.00		
(URL)				
TAB, PO, 0.6 mg, 100s ea	00677-1683-01	25.99		
1000s ea	00677-1683-10	174.99		
(Watson)				
TAB, PO, 0.6 mg, 100s ea	00591-0944-01	19.30		
1000s ea	00591-0944-10	173.70		
(Weck-Ward)				
TAB, PO, 0.6 mg, 100s ea	00143-1201-01	25.99		
100s ea UD	00143-1201-25	32.25		
1000s ea	00143-1201-10	172.25		
(Allscripts)				
REPACK				
TAB, PO, 0.6 mg, 30s ea	54868-0295-00	7.79		
(DHS, Inc.)				
REPACK				
TAB, PO, 0.6 mg, 30s ea	55887-0718-30	7.45		
60s ea	55887-0718-60	14.65		
90s ea	55887-0718-90	22.05		
(DispenseXpress)				
REPACK				
TAB, PO, 0.6 mg, 30s ea	68115-0413-30	10.99		
(Geneinet)				
REPACK				
TAB, PO, 0.6 mg,				
30s ea UD (BLISTER PACK)	61392-0715-30	4.20		
0.6 mg, 30s ea	61392-0715-39	4.20		
31s ea UD	61392-0715-31	4.34		
32s ea UD	61392-0715-32	4.48		
45s ea UD	61392-0715-45	6.30		
60s ea UD	61392-0715-60	8.40		
90s ea UD	61392-0715-90	12.60		
500s ea UD	61392-0715-57	70.00		
2000s ea UD	61392-0715-54	280.00		
10000s ea UD	61392-0715-51	1400.00		
(PD-Rx Pharm)				
REPACK				
TAB, PO, 0.6 mg, 30s ea	55289-0724-30	21.15		
(REDI-SCRIPT)				
0.6 mg, 100s ea	58864-0119-01	18.40		
(Pharm Corp/America)				
REPACK				
TAB, PO, 0.6 mg, 10s ea	51655-0424-53	2.84		
(Physicians Total Care)				
REPACK				
TAB, PO, 0.6 mg, 100s ea	54868-2258-01	47.59		
0.6 mg, 10s ea	54868-0998-05	4.96		
20s ea	54868-0998-06	6.91		
25s ea	54868-0998-04	7.89		
30s ea	54868-0998-00	8.88		
60s ea	54868-0998-03	14.72		
100s ea	54868-0998-01	22.58		

PROD/MFR	NDC	AWP	DP	DESC
(Quality Care Prod)				
REPACK				
TAB, PO, 0.6 mg, 20s ea	60346-0683-20	4.16		
30s ea	60346-0683-30	4.22		
COLCHICINE/PROBENECID (Par Pharm)				
TAB, PO, 0.5 mg-500 mg,				
100s ea	00172-2193-60	84.30		BP
(Trailon)				
TAB, PO, 0.5 mg-500 mg,				
1000s ea	00603-5315-18	103.50		EE
(Watson)				
TAB, PO, 0.5 mg-500 mg,				
100s ea	00591-5325-01	84.34		BP
(Phys Total Care)				
REPACK				
TAB, PO, 0.5 mg-500 mg,				
30s ea	54868-2179-01	14.05		EE
60s ea	54868-2179-00	25.10		EE
COLD CREAM (Ballpet)				
cream base				
CRE, MA (EMOLLIENT BASE)				
454 gm	51552-0800-06	12.60	9.00	
2270 gm	51552-0800-09	50.40	35.00	
COLDRINE (Breckenridge Pharm)				
cpm/methscopolamine nitrate/pse hcl				
TER, PO (DYE-FREE,CAPLET)				
.5 mg-2.5 mg-30 mg,				
100s ea	51991-0284-01	47.19		
COLDCOUGH (Breckenridge Pharm)				
cpm/dihydrocodeine bitartrate/pse hcl				
SOL, PO (AF,SF,DYE-FREE,GRAPE)				
473 ml, C-III	51991-0222-16	36.46		
COLDCOUGH EXP (Breckenridge Pharm)				
dihydrocodeine bitartrate/pg/pse hcl				
SOL, PO (AF,SF,VANILLIN FRUITY)				
473 ml, C-III	51991-0223-16	41.73		
COLDCOUGH HC (Breckenridge Pharm)				
cpm/hydrocod bit/pse hcl				
SYR, PO (AF,SF,DYE-FREE)				
480 ml, C-III	51991-0285-16	45.92		
COLDCOUGH PD (Breckenridge Pharm)				
cpm/dihydrocodeine bitartrate/phenylephr hcl				
SOL, PO (AF,SF,GRAPE)				
118 ml, C-V	51991-0224-04	16.56		
COLDCOUGH XP (Breckenridge Pharm)				
pg/hydrocod bit/pse hcl				
SOL, PO (AF,SF,DYE-FREE,RED FRUIT)				
473 ml, C-III	51991-0283-16	46.98		
COLDEC (Breckenridge Pharm)				
carbinoxamine mal/pse hcl				
TAB, PO, 4 mg-60 mg,				
100s ea	51991-0858-01	55.95		
COLDEC B (Breckenridge Pharm)				
carbinoxamine mal/pse hcl				
TER, PO (CAPLET)				
8 mg-90 mg,				
100s ea	51991-0866-01	47.95		
COLDEC DS (Breckenridge Pharm)				
carbinoxamine mal/pse hcl				
SOL, PO (AF,SF,DYE-FREE)				
2 mg/5 ml-25 mg/5 ml,				
473 ml	51991-0389-16	32.97		
COLDEC TR (Breckenridge Pharm)				
carbinoxamine mal/pse hcl				
TER, PO, 8 mg-120 mg,				
100s ea	51991-0868-01	109.95		
COLDEX-A (URL)				
cpm/phenylepn hcl/phenylpiroxamine cit				
TER, PO (CAPLET)				
4 mg-20 mg-40 mg,				
100s ea	00677-1573-01	54.65		
COLDMIST DM (Breckenridge Pharm)				
dm/pg/pse hcl				
SOL, PO (AF,SF,DYE-FREE)				
473 ml	51991-0287-16	38.30		
SYR, PO, 473 ml	51991-0287-16	38.30		
TER, PO (CAPLET)				
32 mg-595 mg-48 mg,				
100s ea	51991-0145-01	54.50		
COLDMIST JR (Breckenridge Pharm)				
guaifenesin/pseudoephedrine hydrochloride				
TER, PO, 595 mg-48 mg,				
100s ea	51991-0288-01	38.32		

PROD/MFR	NDC	AWP	DP	DESC
COLDMIST LA (Breckenridge Pharm)				
guaifenesin/pseudoephedrine hydrochloride				
TER, PO, 795 mg-85 mg,				
100s ea	51991-0867-01	43.95		
COLDMIST S (Breckenridge Pharm)				
guaifenesin/pseudoephedrine hydrochloride				
SYR, PO (AF,GRAPE)				
200 mg/5 ml-40 mg/5 ml,				
473 ml	51991-0310-16	26.15		
COLDTUSS (Breckenridge Pharm)				
cpm/hydrocod bit/pse hcl				
SYR, PO (BANANA)				
473 ml, C-III	51991-0291-16	49.95		
COLDTUSS SR (URL)				
cpm/dm/phenylepn hcl				
SYR, PO (AF,STRAWBERRY)				
473 ml	00677-1674-33	31.50		
COLESEVELAM HYDROCHLORIDE				
(Sankyo Pharma) *See WELCHOL*				
COLESTID (Pharmacia Corp)				
colestipol hydrochloride				
PDR, PO, 5 gm/packet,				
30s ea	00009-0268-01	60.46		
90s ea	00009-0268-04	181.37		
5 gm/scoopful,				
300 gm	00009-0269-17	71.99		
500 gm	00009-0269-02	119.98		
TAB, PO, 1 gm, 120s ea	00009-0458-03	75.90		
COLESTID FLAVORED (Pharmacia Corp)				
colestipol hydrochloride				
PDR, PO (7.5 GM PACKET)				
5 gm/7.5 gm,				
60s ea	00009-0278-03	141.95		
450 gm	00009-0278-05	94.84		
(Physicians Total Care)				
REPACK				
PDR, PO, 5 gm/7.5 gm,				
7.5 gm 30s	54868-3961-00	54.45		
COLESTIPOL HYDROCHLORIDE				
(Pharmacia Corp) *See COLESTID*				
(Pharmacia Corp) *See COLESTID FLAVORED*				
COLFED-A (Breckenridge Pharm)				
cpm/pse hcl				
CER, PO, 8 mg-120 mg,				
100s ea	51991-0145-01	19.95		
(DRx)				
REPACK				
CER, PO, 8 mg-120 mg,				
10s ea	55045-1295-03	8.90		
20s ea	55045-1295-07	9.45		
COLNIST (Clint)				
brompheniramine maleate				
SOL, IJ (VIAL)				
10 mg/ml, 10 ml	55553-0602-10	14.75		
COLODROPS PEDIATRIC (A. S. Maria)				
hyoscyamine sulfate				
LIQ, PO (AF,SF,DROPS)				
0.125 mg/ml, 30 ml	12539-0215-30	12.00		
COLISTIMETHATE SODIUM (Meditech)				
POW, NA, 1 gm	38779-1283-06	178.50		
5 gm	38779-1283-03	693.00		
(Monarch) *See COLY-MYCIN M*				
(PCCA)				
POW, NA (USP)				
1 gm	51927-2101-00	210.00		
(X-Gen)				
PDS, IJ (VIAL,STERILE)				
150 mg, ea	39822-0615-01	57.00		AF
COLISTIN SULFATE (Paddock)				
POW, NA (U.S.P.)				
ea	00574-0417-01	509.25		
(Spectrum Pharmacy Prod)				
POW, NA (U.S.P.)				
ea	49452-2213-01	1268.00		
COLLAGEN, BOVINE/GLYCOSAMINOGLYCANS				
(Integra LifeSciences Corp) *See INTEGRA BILAYER MATRIX WOUND DRESSING*				
(Integra LifeSciences Corp) *See INTEGRA DERMAL REGENERATION TEMPLATE*				
COLLAGENASE (PCCA)				
POW, NA, 1 ml	51927-2377-00	2.55		
(Reza Pharm) *See SANTYL*				

Exhibit C

2009 RED BOOK®

PHARMACY'S FUNDAMENTAL REFERENCE™

113th YEAR OF PUBLICATION

Executive Vice President, PDR: Thomas Rice
Vice President, Product Management: Cy Caine
Vice President, Publishing & Operations: Valerie Berger
Vice President, Clinical Relations: Mukesh Mehta, RPh
Vice President, Finance: Donna Santarpia
Vice President, Strategy & Business Development: Ray Zoeller
Senior Director, Copy Sales: Bill Gaffney
Senior Director, Sales Operations: Dawn Carfora
Senior Product Manager: Richard Buchwald
Director of Marketing: Kim Marich
Senior Promotion Manager: Linda Levine
Director of Sales: Eileen Bruno
Account Manager: Nick W. Clark
Sales Associate: Janet Wallendal

Senior Director, Editorial & Publishing: Bette LaGow
Senior Director, Client Services: Stephanie Struble
Manager, Clinical Services: Nermin Shenouda, PharmD
Manager, Product and Pricing Data: Deborah Siegfried, PharmD
Drug Information Specialists: Kay Elliott; Cindy Fronsoe; Deepali Gaitonde, PharmD; Michelle Johnson; Traci Kellam; Susie Lee; Debbie Maloney, PharmD; Anila Patel, PharmD; Pat Shofi, RPh; Gwen Smith, PharmD; Christine Sunwoo, PharmD; Greg Tallis, RPh; Kathy Voeck
Manager, Editorial Services: Lori Murray
Associate Editor: Jennifer Reed
Manager, Customer Service: Todd Taccetta

Director, PDR Production: Jeffrey D. Schaefer
Production Manager, PDR: Steven Maher
Manager, Production Purchasing: Thomas Westburgh
Senior Print Production Manager: Dawn Dubovich
Format Editor: Alex Nowalk
Vendor Management Specialist: Gary Lew

Manager, Art Department: Livio Udina
Electronic Publishing Designer: Carrie Spinelli Faeth
Digital Imaging Manager: Christopher Husted
Digital Imaging Coordinator: Michael Labruyere



THOMSON REUTERS

ISBN: 978-1-56363-706-3

KEY TO Rx PRODUCT LISTINGS

How to Find an Rx Product

The layout of *Red Book*® product listings allows for easy identification of Rx products, manufacturer names, generic cross-references, and repackagers of pharmaceutical products. It also identifies Federal Upper Limit prices for Medicaid reimbursement from the Centers for Medicare and Medicaid Services (CMS). Products are listed alphabetically by their prevailing names, as explained below. (For information on how to locate and interpret OTC and non-drug product listings, refer to Section 10.)

Product quantities appear in National Council for Prescription Drug Programs (NCPDP) standard billing units (e.g., ea, ml, gm). Please see Section 6, "Drug Reimbursement Information," for information on the NCPDP standard. A conversion table can be found in Section 2, "Clinical Reference Guide."

Trademarked Name: For branded products, detailed information is found under the brand name rather than the generic name; e.g., "Valium" product information is listed under "Valium" rather than under diazepam. However, you will find a cross-reference under Roche Labs, the manufacturer of Valium, in the diazepam listing.

VALIUM (Roche Labs)
diazepam
TAB, PO, 10 mg,
100s ea, C-IV ..... **00140-0806-01** 286.12 **AB**

Generic Name: In-depth product information on generic products can be found by locating the generic product name, under which the various manufacturers, suppliers, or distributors are listed alphabetically, e.g., diazepam features several dozen generic manufacturers. Manufacturers listed under their trademarked product name feature a cross-reference to that name.

DIAZEPAM
FUL
TAB, PO, 2 mg, 100s ea 2.09
(Hospira, Inc)
INJ, IJ (AMP)
5 mg/ml,
2 ml 10s, C-IV ..... **00074-1273-32** 25.29 **AP**
(Roche Labs) *See VALIUM*

Single-ingredient generic names are spelled out in full. Multi-ingredient products (two or more) are listed in the alphabetical order of their ingredients using the standard abbreviations listed on the following pages.

Drug Class Symbols

The following descriptive symbols indicate a product's status under the Controlled Substances Act of 1970. They apply to all entries under the product name or dosage form in which they appear. Use these symbols only as a guide. Check the manufacturer's label for definitive information.

C-II	High Potential for Abuse. Prescriptions must be written in ink or typewritten and signed by the practitioner. Verbal prescriptions must be confirmed in writing within 72 hours and may be given only in a genuine emergency. No renewals.
C-III	Some Potential for Abuse. Prescriptions may be oral or written. Up to 5 renewals are permitted within 6 months.
C-IV	Low Potential for Abuse. Prescriptions may be oral or written. Up to 5 renewals are permitted within 6 months.
C-V	Subject to State and Local Regulation. Abuse potential is low; a prescription may not be required.
Rx	Prescription only; not a controlled substance.

How to Read the Listings

The first line of an entry features the product or generic name. CMS Federal Upper Limit price information is provided for all applicable multisource product categories. The **FUL** symbol can be found immediately following the generic product name. A complete listing of Federal Upper Limit prices appears in Section 6, "Drug Reimbursement Information."

Manufacturers are listed alphabetically within generic listings. Repackagers of products feature the **REPACK** symbol next to their names. For trade name listings, generic cross-references appear in lower case on the following line.

A three-letter abbreviation indicates the form of the drug; e.g., CAP indicates capsules, TAB indicates tablets, etc. For a key to additional abbreviations, refer to the table on the following page.

Route of administration, descriptive information, strength, quantity, and drug class symbol (where applicable) appear next, followed by National Drug Code (NDC) number. The Average Wholesale Price (AWP), Direct Price (DP), and the Orange Book Code (OBC) complete the entry for each product. For more information on Orange Book Codes, refer to the next page.



The prices contained in *Red Book* are based on data *reported* by manufacturers. The publisher has not performed any independent analysis of the *actual* prices paid by wholesalers and providers in the marketplace. Thus, *actual* prices paid by wholesalers and providers may well vary from the prices contained in this publication and all prices are subject to change without notice. Further, while care has been exercised in compiling all of the information contained herein, the publisher does not warrant its accuracy. For further explanation, see the section titled "AWP Policy" in the *Red Book* Foreword. Information may be supplemented by subscribing to the monthly *Red Book UPDATE*®, ReadyPrice™, *Red Book* for Windows™, *Red Book* data services, or by obtaining prices published in catalogs or other printed materials disseminated by manufacturers or distributors.

ROUTE OF ADMINISTRATION ABBREVIATIONS

Route of Administration (ROA) refers to the intake or application method of a product. The following abbreviations are used to indicate the ROA:

BC	Buccal	**MR**	Multiple routes
DE	Dental	**NA**	Not applicable
EP	Epidural	**NS**	Nasal
IC	Intracavernosal	**OP**	Ophthalmic
ID	Intradermal	**OT**	Otic
IH	Inhalation	**PL**	Intrapleural
IJ	Injection	**PO**	Oral
IL	Intravesical	**PT**	Intraperitoneal
IM	Intramuscular	**RC**	Rectal
IN	Intrathecal	**SC**	Subcutaneous
IO	Intraocular	**SG**	Subgingival
IP	Implantation	**SL**	Sublingual
IR	Irrigation	**TD**	Transdermal
IT	Intratracheal	**TP**	Topical
IU	Intrauterine	**UR**	Intraurethral
IV	Intravenous	**VG**	Vaginal
MM	Mucous membrane		

PROD/MFR	NDC	AWP	DP	OBC
COFFEE FLAVOR (PCCA)				
flavoring aid				
POW, NA (ARTIFICIAL,COFFEE)				
1 gm	51927-3455-00	0.32		
SOL, NA, 1 ml	51927-3299-00	0.90		
COGENTIN (Ovation Pharma)				
benztropine mesylate				
SOL, IJ (5X2ML)				
1 mg/ml, 2 ml 5s	67386-0611-52	386.82	46.03	
(Phys Total Care)				
REPACK				
SOL, IJ (AMP)				
1 mg/ml, 2 ml 6s	54868-2429-01	51.23		
COGNEX (Scios)				
tacrine hydrochloride				
CAP, PO, 10 mg, 120s ea	59630-0190-12	350.05		
20 mg, 120s ea	59630-0191-12	350.05		
30 mg, 120s ea	59630-0192-12	350.05		
40 mg, 120s ea	59630-0193-12	350.05		
COLA (Gallipot)				
SYR, NA, 118.28 ml	51552-0291-04	3.08		
473 ml	51552-0291-06	10.29		
3785 ml	51552-0291-08	27.16		
(PCCA) *See COCA COLA*				
COLA FLAVOR (PCCA)				
flavoring aid				
SOL, NA (CAFFEINE-FREE)				
1 ml	51927-3414-00	0.30		
COLA NUT				
(PCCA) *See KOLA NUT*				
COLAZAL (Salix Pharm)				
balsalazide disodium				
CAP, PO, 750 mg, 280s ea	65649-0101-02	477.67		
500s ea	65649-0101-50	853.00		
COLCHICINE (Consolidated Midland)				
TAB, PO, 0.6 mg, 100s ea	00223-0703-01	3.95		
1000s ea	00223-0703-02	19.75		
(Excellium)				
TAB, PO, 0.6 mg, 100s ea	64125-0184-01	25.99		
1000s ea	64125-0184-10	174.99		
(Gallipot)				
POW, NA (1X1GM,USP)				
1 gm	51552-0981-01	54.95	39.25	
(PCCA)				
POW, NA (U.S.P.)				
1 gm	51927-1895-00	204.00		
(Spectrum Pharmacy)				
POW, NA (U.S.P.)				
1 gm	49452-2210-02	182.00		
5 gm	49452-2210-03	689.50		
(Vision)				
TAB, PO (USP)				
0.6 mg, 100s ea	68013-0001-01	33.32		
500s ea	68013-0001-05	166.60		
1000s ea	68013-0001-10	333.20		
(West-Ward)				
TAB, PO, 0.6 mg, 100s ea	00143-1201-01	26.99		
100s ea UD	00143-1201-25	33.25		
1000s ea	00143-1201-10	172.25		
(Allscripts)				
REPACK				
TAB, PO, 0.6 mg, 30s ea	54569-0236-06	12.78		
60s ea	54569-0236-83	25.55		
(Bryant Ranch)				
REPACK				
TAB, PO, 0.6 mg, 20s ea	63629-2651-01	5.00		
(Core)				
REPACK				
TAB, PO, 0.6 mg, 20s ea	33358-0894-20	5.13		
30s ea	33358-0894-30	9.73		
(DHS, Inc.)				
REPACK				
TAB, PO, 0.6 mg, 30s ea	55887-0718-30	12.09		
(DispenseXpress)				
REPACK				
TAB, PO, 0.6 mg, 30s ea	68115-0413-30	34.65		
(Dispensing Solutions)				
REPACK				
TAB, PO, 0.6 mg, 50s ea	66336-0401-50	12.18		
(Dist)				
REPACK				
TAB, PO, 0.6 mg, 12s ea	55045-2420-04	3.12		
20s ea	55045-2420-02	5.20		
30s ea	55045-2420-08	7.80		
100s ea	55045-2420-01	26.00		
(HomeMed)				
REPACK				
TAB, PO, 0.6 mg, 10s ea	51655-0424-53	2.64		
COLCHICINE (Palmetto)				
REPACK				
TAB, PO, 0.6 mg, 60s ea	23490-5367-04	24.18		
COLCHICINE (PD-Rx Pharm)				
REPACK				
TAB, PO, 0.6 mg, 10s ea	55289-0279-10	9.38		
(USP)				
0.6 mg, 30s ea	55289-0279-30	12.23		
(REDI-SCRIPT)				
0.6 mg, 100s ea	58864-0119-01	26.80		
(Phys Total Care)				
REPACK				
TAB, PO, 0.6 mg, 10s ea	54868-0998-05	4.96		
20s ea	54868-0998-06	6.21		
25s ea	54868-0998-04	7.02		
30s ea	54868-0998-00	7.83		
60s ea	54868-0998-03	12.66		
100s ea	54868-0998-01	19.11		
(Quality Care Prod)				
REPACK				
TAB, PO, 0.6 mg, 30s ea	35356-0239-30	32.20		
(Stat Rx)				
REPACK				
TAB, PO, 0.6 mg, 20s ea	16590-0268-20	10.00		
30s ea	16590-0268-30	15.00		
60s ea	16590-0268-60	30.00		
COLCHICINE/PROBENECID				
(Rising) *See PROBENECID AND COLCHICINE*				
(Truxton)				
TAB, PO, 0.5 mg-500 mg,				
1000s ea	00463-6316-10	103.50		EE
(Watson Labs)				
TAB, PO, 0.5 mg-500 mg,				
100s ea	00591-5325-01	84.34		BP
(Phys Total Care)				
REPACK				
TAB, PO, 0.5 mg-500 mg,				
30s ea	54868-2178-01	86.58		EE
60s ea	54868-2179-00	168.69		EE
COLD CREAM (Gallipot)				
cream base				
CRE, NA (EMMOLIENT BASE)				
454 gm	51552-0809-06	12.60	9.00	
2270 gm	51552-0809-09	50.40	36.00	
COLDAMINE (Breckenridge Pharm)				
cpm/methscopolamine nitrate/pse hcl				
TER, PO (DYE-FREE,CAPLET)				
8 mg-2.5 mg-90 mg,				
100s ea	51991-0284-01	47.19		
COLDCOUGH (Breckenridge Pharm)				
cpm/dihydrocodeine bitartrate/pse hcl				
SOL, PO (AF,SF,DYE-FREE,GRAPE)				
473 ml, C-III	51991-0222-16	35.46		
COLDCOUGH HC (Breckenridge Pharm)				
cpm/hydrocod bit/pse hcl				
SYR, PO (AF,SF,DYE-FREE)				
480 ml, C-III	51991-0206-16	45.92		
COLDCOUGH HCM (Breckenridge Pharm)				
hydrocod bit/pse hcl				
SOL, PO (AF,SF,DYE-FREE)				
3 mg/5 ml-15 mg/5 ml,				
473 ml, C-III	51991-0306-16	28.47		
COLDCOUGH PD (Breckenridge Pharm)				
cpm/dihydrocodeine bitartrate/phenyleph hcl				
SOL, PO (AF,SF,GRAPE)				
118 ml, C-V	51991-0224-04	15.55		
COLESEVELAM HYDROCHLORIDE				
(Daiichi Sankyo) *See WELCHOL*				
COLESTID (Pfizer U.S.P.G.)				
colestipol hydrochloride				
PDR, PO, 5 gm/packet,				
30s ea	00009-0260-01	77.82	64.85	
90s ea	00009-0260-04	233.45	194.54	
5 gm/scoopful,				
300 gm	00009-0260-17	92.68	77.23	
500 gm	00009-0260-02	154.45	128.71	
TAB, PO, 1 gm, 120s ea	00009-0450-03	97.70	81.42	
COLESTID FLAVORED (Pfizer U.S.P.G.)				
colestipol hydrochloride				
PDR, PO (7.5 GM PACKET)				
5 gm/7.5 gm,				
60s ea	00009-0370-03	182.72	152.27	
450 gm	00009-0370-05	127.87	106.56	
(Phys Total Care)				
REPACK				
PDR, PO, 5 gm/7.5 gm,				
7.5 gm 30s	54868-3961-00	74.97		
COLESTID GRAN (Phys Total Care)				
colestipol hydrochloride				
PDR, PO, 5 gm/scoopful,				
500 gm	54868-3860-00	146.39		
COLESTIPOL (Phys Total Care)				
colestipol hydrochloride				
TAB, PO, 1 gm, 120s ea	54868-0610-00	203.91		
COLESTIPOL HYDROCHLORIDE (Global Pharm)				
PDR, PO, 5 gm/packet,				
30s ea	00115-5212-16	59.89		AB
(USP)				
5 gm/packet,				
90s ea	00115-5212-29	179.65		AB
(USP,W/SCOOP,TASTELESS)				
5 gm/scoopful,				
500 gm	00115-5213-02	118.85		AB
TAB, PO (FILM-COATED)				
1 gm, 120s ea	00115-5211-16	78.94		AB
(Pfizer U.S.P.G.) *See COLESTID*				
(Pfizer U.S.P.G.) *See COLESTID FLAVORED*				
COLESTIPOL HYDROCHLORIDE, MICRONIZED				
(Greenstone) *See MICRONIZED COLESTIPOL HYDROCHLORIDE*				
COLFED-A (Breckenridge Pharm)				
cpm/pse hcl				
CER, PO, 8 mg-120 mg,				
100s ea	51991-0145-01	135.00		
(DRx)				
REPACK				
CER, PO, 8 mg-120 mg,				
10s ea	55045-1295-03	6.90		
20s ea	55045-1295-07	13.80		
COLIDROPS PEDIATRIC (A. G. Marin)				
hyoscyamine sulfate				
LIQ, PO (AF,SF,DROPS)				
0.125 mg/ml, 30 ml	12539-0315-30	12.00		
COLISTIMETHATE (APP)				
colistimethate sodium				
PDS, IJ (USP,LYOPHILIZED CAKE)				
150 mg, ea	63323-0393-05	57.00		
(Phys Total Care)				
REPACK				
PDS, IJ, 150 mg, ea	54868-5812-00	114.18		
COLISTIMETHATE SODIUM				
(APP) *See COLISTIMETHATE*				
(JHP) *See COLY-MYCIN M PARENTERAL*				
(Medisca)				
POW, NA, 1 gm	36770-1203-06	176.50		
5 gm	36770-1203-03	693.00		
(Paddock)				
PDS, IJ (VIAL,STERILE)				
150 mg, ea	00574-0858-01	57.00		AP
(PCCA)				
POW, NA (USP)				
1 gm	51927-2101-00	210.00		
(X-Gen)				
PDS, IJ (VIAL,STERILE)				
150 mg, ea	39822-0615-01	57.00		AP
COLISTIN SULFATE (Spectrum Pharmacy)				
POW, NA (U.S.P.)				
ea	49452-2213-01	2397.50		
COLLAGEN HEMOSTAT				
(Davol) *See AVITENE MICROFIBRILLAR COLLAGEN HEMOSTAT*				
(Davol) *See AVITENE ULTRAFOAM COLLAGEN*				
(Davol) *See ENDOAVITENE*				
(Davol) *See SYRINGEAVITENE*				
COLLAGEN HYDROLYSATE (PCCA)				
collagen, bovine				
POW, NA (1X1GM)				
1 gm	51927-1132-00	0.27		
COLLAGEN NERVE ENCASEMENT				
(Integra LifeSciences Corp) *See NEURAGEN*				
(Integra LifeSciences Corp) *See NEURAWRAP*				
(Stryker) *See NEUROMATRIX*				
(Stryker) *See NEUROMEND COLLAGEN NERVE WRAP*				

Exhibit D

First DataBank

Of Indianapolis

COPY

New Product Submission Form

NDC / ~~UPC~~ Number: 64125-104

Product Name: Colchicine 0.6mg Tablets

Effective (Launch) Date: 1/99 Rx or OTC ? Rx

Dosage Form: Tablet Package Size: 100's and 1000's

Package Description (bottle, vial, ampule, ect): Bottle

Active Ingredients and Strengths:
COPIES OF LABELS OR PACKAGE INSERTS ARE PREFERRED

Colchicine 0.6mg

DP: — WAC: — AWP: ~~0.0562~~ 0.010938

If dosage form is a tablet / capsule please provide the following imprint information:

Shape: Round Color(s): White

CAPSULE
Imprint: —

TABLET
Side one imprint: EP/104 Side two imprint: Plain

Coated ? — Scored ? —

FIRSTDATABANK
Point-of-Care Knowledge Bases

New Product Submission Form

Drug Data File (NDDF). Please make copies of this form for each add.

NDC Number	64125-104-10
UPC Number	–
Product Name	Colchicine 0.6 mg
RX or OTC	RX
Package Size (ml, gm, each)	1000's
Dosage Form (tablet, capsule, powder filled vial, ampul, ointment, etc...)	Tablet
Wholesale (Distributor) Price	–
Direct Price	–
AWP Price	56.28
Effective Date (start ship date or effective date for pricing)	Jan 99
Active Ingredients & strengths (Package Insert and Label are preferred.)	Colchicine USP

Company Name: Excellium Pharmaceutical Inc
Your Name: Hasmukh G. Doshi

FIRSTDATABANK
Point-of-Care Knowledge Bases

COPY

New Product Submission Form

Drug Data File (NDDF). Please make copies of this form for each add.

NDC Number	64125-104-01
UPC Number	-
Product Name	Colchicine 0.6mg
RX or OTC	Rx
Package Size (ml, gm, each)	100's
Dosage Form (tablet, capsule, powder filled vial, ampul, ointment, etc...)	Tablet
Wholesale (Distributor) Price	-
Direct Price	-
AWP Price	5.63
Effective Date (start ship date or effective date for pricing)	Jan 99.
Active Ingredients & strengths (Package Insert and Label are preferred.)	Colchicine USP.

Company Name: Excellium Pharmaceutical, Inc.
Your Name: Hasmukh Doshi

TAB 3

KEVIN E. GAUT (SBN 117352), keg@msk.com
PATRICIA H. BENSON (SBN 60565)
phb@msk.com
MITCHELL SILBERBERG & KNUPP LLP
11377 West Olympic Boulevard
Los Angeles, California 90064-1683
Telephone: (310) 312-2000
Facsimile: (310) 312-3100

Attorneys for Defendant
Watson Pharmaceuticals, Inc.

[SEE SIGNATURE PAGES AND CONTINUED CAPTION FOR LIST OF ADDITIONAL ATTORNEYS AND PARTIES JOINING IN THIS MOTION]

UNITED STATES DISTRICT COURT

CENTRAL DISTRICT OF CALIFORNIA

MUTUAL PHARMACEUTICAL COMPANY, INC., a Pennsylvania corporation, AR SCIENTIFIC, INC., a Delaware corporation, and AR HOLDING COMPANY, INC., a Delaware corporation,

Plaintiffs,

v.

WATSON PHARMACEUTICALS, INC., a Nevada corporation, WESTWARD PHARMACEUTICAL CORP, a Delaware corporation, GENERICS BIDCO I, LLC dba QUALITEST PHARMACEUTICALS, a Delaware corporation, VISION PHARMA, LLC, a New Jersey corporation; and EXCELLIUM PHARMACEUTICAL, INC., a New Jersey corporation,

Defendants.

CASE NO. CV 09-05700 PA (RCx)

The Honorable Percy Anderson

DECLARATION OF ANDREW BOYER IN SUPPORT OF JOINT OPPOSITION TO MOTION FOR PRELIMINARY INJUNCTION

Date: TBD (if necessary)
Time:
Courtroom: 15

RICHARD A. JONES (SBN 135248),
rjones@cov.com
ANTHONY HERMAN (*Pro Hac Vice Pending*),
aherman@cov.com
DAMARA CHAMBERS (*Pro Hac Vice Pending*),
dchambers@cov.com
COVINGTON & BURLING LLP
One Front Street
San Francisco, California 94111-5356
Telephone: (415) 591-6000
Facsimile: (415) 591-6091

Attorneys for Defendant
Excellium Pharmaceutical, Inc.

ROBERT P. CHARROW (SBN 044962),
charrowr@gtlaw.com
GREENBERG TRAURIG LLP
2101 L. Street, N.W. Suite 1000
Washington, D.C. 20037
Telephone: (202) 533-2362
Facsimile: (202) 261-0164

Attorneys for Defendant
Vision Pharma LLC

DECLARATION OF ANDREW BOYER

I, ANDREW BOYER, declare:

1. I am Senior Vice President, Sales and Marketing for Watson Pharma, Inc., a wholly owned subsidiary of Watson Pharmaceuticals, Inc. Watson Pharma, Inc. markets and distributes products for the subsidiaries of Watson Pharmaceuticals, Inc. that manufacture pharmaceutical products. (Hereafter, Watson Pharmaceuticals, Inc. and Watson Pharma, Inc. are referred to collectively as "Watson."). Except as expressly stated herein, I have personal knowledge of the following facts and, if called and sworn as a witness, could and would competently testify thereto.

2. In the year 2000, Watson acquired another pharmaceutical company called Schein Pharmaceutical Inc. ("Schein"). Among the products that Schein was then manufacturing and distributing was a 0.6 mg oral colchicine tablet (" oral colchicine"). Based on the books and records of Schein, which became the books and records of Watson, and on which Watson relies, I can state that Schein had been manufacturing and distributing its oral colchicine product since 1992. After Watson acquired Schein, Watson continued manufacturing and distributing this product but under the Watson name, and with a different National Drug Code ("NDC") number. (An NDC number is a unique 10 digit, 3 segment number that identifies the vendor, product and package size). To the best of my knowledge, the FDA has never sent a warning letter to Watson about its oral colchicine or directed Watson to stop selling its oral colchicine.

3. I am aware that for many years before Mutual Pharmaceuticals, Inc. ("Mutual") obtained FDA approval for the oral colchicine product it calls COLCRYS, Mutual sold the identical product (*i.e.*, 0.6 mg oral colchicine tablets) without FDA approval. I know from information in the marketplace that Mutual was selling its unapproved colchicine at least as recently as 2006.

4. I know from information in the marketplace that in 2001, Mutual's oral colchicine was being sold to wholesalers at the price of $9.06 per 100 pills, or approximately $.09 per pill. I

also know from information currently in the marketplace that that Mutual now is selling the same .06 mg oral colchicine product, but under the COLCRYS brand name, at a price of $485.00 per 100 pills, or $4.85 per pill – an increase of over 5000%. Watson currently is not selling oral colchicine. However, the most recent price at which Watson sold its oral colchicine product to wholesalers (as of June 5, 2009) was $9.00 per 100 pills, or $.09 per pill.

5. Although Watson currently is not selling oral colchicine, those to whom it has sold that product presumably still have in their inventory oral colchicine they previously purchased from Watson. Watson does not have the ability to cause such third parties to stop selling the oral colchicine they purchased, nor does it have the ability to tell wholesalers or price list publishers to stop listing Watson's product. Further, advising price list publishers or wholesalers that Watson's oral colchicine is "obsolete" would mean only that the wholesalers would not place any orders with Watson in the future; it would not stop sales of oral colchicine that the wholesalers have previously purchased and that is still in their inventory.

6. I have been advised that Mutual submitted the declaration of someone named James O'Donnell asserting that Watson's oral colchicine shows up as a generic equivalent to COLCRYS in the online ordering database of AmerisourceBergen Corporation ("ABC"), and impling that Watson listed its product as the generic equivalent to COLCRYS in the HDMA (Healthcare Distribution Management Association) standard product information form that it submitted to ABC. Watson has never communicated to ABC that Watson's oral colchicine is the generic equivalent to COLCRYS, nor did Watson include such a representation in any HDMA form it submitted to ABC. Watson has no control over whether or if ABC identifies a product as the generic equivalent of another product. Attached hereto collectively as Exhibit 1 are correct copies of the HDMA forms that Watson submitted to wholesalers, including ABC, in or about early June, 2009. As those forms show, Watson did not fill in the spaces for "Orange Book Rating" (the Orange Book is a list of FDA-approved drugs, and includes therapeutic equivalency

ratings) or "Brand Name Equivalent." Watson has not submitted any HDMA forms to ABC for colchicine since that time.

7. Watson's relationships with its customers, and Watson's reputation, will be seriously damaged if it is enjoined from selling its oral colchicine, because Watson will not be able to fulfill orders for product that its customers want and need, under circumstances where the FDA has not banned the sale of the product. In large part, Watson's ability to sell products that are also available from other suppliers depends on Watson's reputation as a consistent and reliable supplier.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Executed this 15th day of September, 2009, at Morristown, New Jersey.

Andrew Boyer

EXHIBIT 1

Date: _____

PRODUCT INFORMATION

Manufacturer/Broker Name: Watson Laboratories Number: _____
Product Name: Colchicine Tablets
Product ID Number: _____
☒ NDC 00591-0944-10 ☒ UPC/GTIN # 3-0591094410-0
Description: Colchicine .6mg Tablets 1000
Address: _____
City, State, Zip: _____
Key Contact: David Schmidt Fax: 920-446-3693
Phone Number: 920-446-3284 Ext: _____
Phone Number: _____ Ext: _____
Is the Product? ☐ Direct Ship Item ☐ Drop Ship Item
Is the Product a Controlled Drug? ☐ Yes ☒ No
If Yes, Schedule Number: _____
Is this ARCOS reportable? ☐ Yes ☒ No
Is this Product a Legend Device? ☐ Yes ☒ No
Country of Origin: USA
Harmonization Code Number for International Shipping: _____
Is this product a Hazardous Material or Cytotoxic Agent?
☐ Yes ☒ No If yes, provide additional information on page 2.
Attach copy of Material Safety Data Sheet (MSDS)
Attach Package Insert

SPECIAL HANDLING AND STORAGE REQUIREMENTS

a. Temperature – Indicate the normal temperature range for this product.

I.	Controlled Room Temperature (68° – 77° F)	☐
II.	Room Temperature (59° – 86° F)	☒
III.	Excessive Heat (>104° F)	☐
IV.	Cool (46° – 59° F)	☐
V.	Refrigerated (36° – 46° F)	☐
VI.	Frozen (-4° – 14° F)	☐
VII.	No Requirement	☐

b. Are temperature excursions permitted/allowed for product? ☐ Yes ☐ No
If Yes, provide the temperature range and hours duration:
_____ and _____

c. Are there additional storage and shipping requirements? ☐ Yes ☐ No
If yes, please provide on page 2.

ADDITIONAL PRODUCT INFORMATION

Is there a minimum order quantity?
If yes, ☐ Case ☐ Carton ☐ Item
Number of Pieces? _____
Shelf Life: 24 Months
Whsl. Code #: _____
Fineline Code: _____
Is Item? ☐ Unit Dose ☐ Unit of Use
If Unit Dose, is item bar coded to unit dose for Hospital tracking purposes?
☐ Yes ☐ No
Will handling data change in the first:
6 months? ☐ Yes
9 months? ☐ Yes
12 months? ☐ Yes
Unknown? ☐ Yes

ITEM AND PACKING INFORMATION

Size/Strength /Form	Unit Of Sale	UPC Code	Mstr. Shpr.	Inner Case Pk	Wght. Lbs.	Cube	Case Dimensions	Item Dimensions	Pallet Dimensions	# Cases/ Pallet
1000 .6mg Tablet	☒ Bottle ☐ Box ☐ Glass jar ☐ Ampule ☐ Other	Case:	144	12	Case: 32.45lbs		Depth: 15.50"	Depth: 3.90"	Depth:	30
		Carton:			Carton:		Height: 12.00"	Height: 3.90"	Height:	
		Item: 305910944100			Item: 0.21 lbs		Width: 12.00"	Width: 1.90"	Width:	

For Generic Drug Products: I. Orange Book Rating: _____ II. Product Color: White
III. Brand Name Equivalent: _____ IV. Generic Name For Brand: _____

COST INFORMATION

	Regular Cost ($)	Purchase Allowance ☐ OI ☐ BB $	Purchase Allowance ☐ OI ☐ BB %	Distribution Allowance ☐ OI ☐ BB $	Distribution Allowance ☐ OI ☐ BB %	Invoice Cost ($)	Net Cost ($)	Mfr's AWP	Avg Retl Price ($)	SRP ($)	Excise Tax
DZ											
EA	$69.50							$174.99			
PPK											

This offer is made on a proportionally equal basis to all sellers' accounts completive with customer. Signature: _____

Revised 02/21/06

HDMA Standard Product Information — Pharmaceutical Products

Item Description: Colchicine .6mg Tablets 1000 Manufacturer: Watson Pharmaceuticals, Inc.

If additional information is necessary, provide on right of page or as attachment.

HAZARDOUS MATERIAL INFORMATION

Is this product:

- a) Cytotoxic? ☐ Yes ☒ No
- b) Carcinogen? ☐ Yes ☒ No
- c) Inhalation Hazard? ☐ Yes ☒ No
- d) Contact Hazard? ☐ Yes ☒ No

Is this item considered a carcinogen? ☐ Yes ☒ No

Is this item an aerosol requiring special storage? ☐ Yes ☒ No

Does this product require special clean-up instructions? ☐ Yes ☒ No

If yes, attach MSDS with special instructions.

Department of Transportation (DOT) I.D. Number: _____

Hazard Class/ORM Code: _____

OSHA/DOT CHEMICAL STORAGE CLASS

Please check appropriate Class(s) for this product.

☐ ORGANIC	☐ ANTINEOPLASTIC
☐ INORGANIC	☐ STEROID/ANDROGEN
☐ CORROSIVE/OXIDIZER	☐ ESSENTIAL CHEMICAL
☐ AEROSOL	☐ PRECURSOR CHEMICAL (Describe below)
☐ AEROSOL CLASS	☐ MAXIMUM QTY LEVEL

Is the product restricted for air shipping?

- ☐ Passenger
- ☐ Cargo
- ☐ Passenger & Cargo

Precursor Chemical:			Size/Strength
Ephedrine	☐ Yes	☐ No	_____
Pseudoephedrine	☐ Yes	☐ No	_____
Phenylpropanolamine	☐ Yes	☐ No	_____

ADDITIONAL STORAGE AND SHIPPING REQUIREMENTS

- Is this product to be shipped to customers on ice? ☐ Yes ☐ No
- Is this product to be shipped to customers on dry ice? ☐ Yes ☐ No
- Does this product require refrigerated truck for transport? ☐ Yes ☐ No
- Is this Product State Regulated? ☐ Yes ☐ No
  - If yes, list states on the right or as an attachment.
- Are there special returns requirements? ☐ Yes ☐ No
  - If yes, provide requirements in the space to the right or as attachment.

ADDITIONAL INFORMATION AS NECESSARY

5

Revised 02/21/06

HDMA Standard Product Identification Form — Pharmaceuticals

☐ New Item ☐ Promotional ☐ Open Stock ☐ Post Launch Change

Date: _____ Page 1 of 2

PRODUCT INFORMATION

Manufacturer/Broker Name: Watson Laboratories Number: _____

Product Name: Colchicine Tablets

Product ID Number: _____

☒ NDC 00591-0944-01 ☒ UPC/GTIN # 3-0591094401-8

Description: Colchicine .6mg Tablets 100

Address: _____

City, State, Zip: _____

Key Contact: Tony Giannone Fax: 610-746-2964

Phone Number: 610-746-4964 Ext: _____

Phone Number: _____ Ext: _____

Is the Product? ☐ Direct Ship Item ☐ Drop Ship Item

Is the Product a Controlled Drug? ☐ Yes ☒ No

If Yes, Schedule Number: _____

Is this ARCOS reportable? ☐ Yes ☒ No

Is this Product a Legend Device? ☐ Yes ☒ No

Country of Origin: USA

Harmonization Code Number for International Shipping: _____

Is this product a Hazardous Material or Cytotoxic Agent?

☐ Yes ☒ No If yes, provide additional information on page 2.

Attach copy of Material Safety Data Sheet (MSDS)

Attach Package Insert

SPECIAL HANDLING AND STORAGE REQUIREMENTS

a. Temperature – Indicate the normal temperature range for this product.

I.	Controlled Room Temperature (68° – 77° F)	☐
II.	Room Temperature (59° – 86° F)	☒
III.	Excessive Heat (>104° F)	☐
IV.	Cool (46° – 59° F)	☐
V.	Refrigerated (36° – 46° F)	☐
VI.	Frozen (-4° – 14° F)	☐
VII.	No Requirement	☐

b. Are temperature excursions permitted/allowed for product? ☐ Yes ☐ No

If Yes, provide the temperature range and hours duration:

_____ and _____

c. Are there additional storage and shipping requirements? ☐ Yes ☐ No

If yes, please provide on page 2.

ADDITIONAL PRODUCT INFORMATION

Is there a minimum order quantity?

If yes, ☐ Case ☐ Carton ☐ Item

Number of Pieces? _____

Shelf Life: 24 Months

Whsl. Code #: _____

Fineline Code: _____

Is Item? ☐ Unit Dose ☐ Unit of Use

If Unit Dose, is item bar coded to unit dose for Hospital tracking purposes?

☐ Yes ☐ No

Will handling data change in the first:

6 months? ☐ Yes

9 months? ☐ Yes

12 months? ☐ Yes

Unknown? ☐ Yes

ITEM AND PACKING INFORMATION

Size/Strength /Form	Unit Of Sale	UPC Code	Mstr. Shpr.	Inner Case Pk	Wght. Lbs.	Cube	Case Dimensions	Item Dimensions	Pallet Dimensions	# Cases/ Pallet
100 .6mg Tablet	☒ Bottle ☐ Box ☐ Glass jar ☐ Ampule ☐ Other _____	Case:	144	12	Case: 8.09 lbs		Depth: 12.50"	Depth: 3.40"	Depth:	60
		Carton:			Carton:		Height: 10.75"	Height: 3.40"	Height:	
		Item: 305910944018			Item: 0.05 lbs		Width: 9.75"	Width: 1.50"	Width:	

For Generic Drug Products: I. Orange Book Rating: _____ II. Product Color: White

III. Brand Name Equivalent: _____ IV. Generic Name For Brand: _____

COST INFORMATION

	Regular Cost ($)	Purchase Allowance ☐ OI ☐ BB $	Purchase Allowance %	Distribution Allowance ☐ OI ☐ BB $	Distribution Allowance %	Invoice Cost ($)	Net Cost ($)	Mfr's AWP	Avg Retl Price ($)	SRP ($)	Excise Tax
DZ											
EA	$9.00							$24.95			
PPK											

This offer is made on a proportionally equal basis to all sellers' accounts completive with customer. Signature: _____

Revised 02/21/06

HDMA Standard Product Information — Pharmaceutical Products

Item Description: Colchicine ,6mg Tablets 100 **Manufacturer:** Watson Pharmaceuticals, Inc.

If additional information is necessary, provide on right of page or as attachment.

HAZARDOUS MATERIAL INFORMATION

Is this product:

- a) Cytotoxic? ☐ Yes ☒ No
- b) Carcinogen? ☐ Yes ☒ No
- c) Inhalation Hazard? ☐ Yes ☒ No
- d) Contact Hazard? ☐ Yes ☒ No

Is this item considered a carcinogen? ☐ Yes ☒ No

Is this item an aerosol requiring special storage? ☐ Yes ☒ No

Does this product require special clean-up instructions? ☐ Yes ☒ No

If yes, attach MSDS with special instructions.

Department of Transportation (DOT) I.D. Number: _____

Hazard Class/ORM Code: _____

OSHA/DOT CHEMICAL STORAGE CLASS

Please check appropriate Class(s) for this product.

☐ ORGANIC	☐ ANTINEOPLASTIC
☐ INORGANIC	☐ STEROID/ANDROGEN
☐ CORROSIVE/OXIDIZER	☐ ESSENTIAL CHEMICAL
☐ AEROSOL	☐ PRECURSOR CHEMICAL (Describe below)
☐ AEROSOL CLASS	☐ MAXIMUM QTY LEVEL

Is the product restricted for air shipping?

- ☐ Passenger
- ☐ Cargo
- ☐ Passenger & Cargo

Precursor Chemical:			Size/Strength
Ephedrine	☐ Yes	☐ No	_____
Pseudoephedrine	☐ Yes	☐ No	_____
Phenylpropanolamine	☐ Yes	☐ No	_____

ADDITIONAL STORAGE AND SHIPPING REQUIREMENTS

- Is this product to be shipped to customers on ice? ☐ Yes ☐ No
- Is this product to be shipped to customers on dry ice? ☐ Yes ☐ No
- Does this product require refrigerated truck for transport? ☐ Yes ☐ No
- Is this Product State Regulated? ☐ Yes ☐ No
  - If yes, list states on the right or as an attachment.
- Are there special returns requirements? ☐ Yes ☐ No
  - If yes, provide requirements in the space to the right or as attachment.

ADDITIONAL INFORMATION AS NECESSARY

Date: _____

PRODUCT INFORMATION

Manufacturer/Broker Name: Watson Laboratories Number: _____
Product Name: Colchicine Tablets
Product ID Number: _____
☒ NDC 00591-0944-10 ☒ UPC/GTIN # 3-0591094410-0
Description: Colchicine .6mg Tablets 1000
Address: _____
City, State, Zip: _____
Key Contact: Tony Giannone Fax: 610-746-2964
Phone Number: 610-746-4964 Ext: _____
Phone Number: _____ Ext: _____
Is the Product? ☐ Direct Ship Item ☐ Drop Ship Item
Is the Product a Controlled Drug? ☐ Yes ☒ No
If Yes, Schedule Number: _____
Is this ARCOS reportable? ☐ Yes ☒ No
Is this Product a Legend Device? ☐ Yes ☒ No
Country of Origin: USA
Harmonization Code Number for International Shipping: _____
Is this product a Hazardous Material or Cytotoxic Agent?
☐ Yes ☒ No If yes, provide additional information on page 2.
Attach copy of Material Safety Data Sheet (MSDS)
Attach Package Insert

SPECIAL HANDLING AND STORAGE REQUIREMENTS

a. Temperature – Indicate the normal temperature range for this product.

I.	Controlled Room Temperature (68° – 77° F)	☐
II.	Room Temperature (59° – 86° F)	☒
III.	Excessive Heat (>104° F)	☐
IV.	Cool (46° – 59° F)	☐
V.	Refrigerated (36° – 46° F)	☐
VI.	Frozen (-4° – 14° F)	☐
VII.	No Requirement	☐

b. Are temperature excursions permitted/allowed for product? ☐ Yes ☐ No
If Yes, provide the temperature range and hours duration:
_____ and _____

c. Are there additional storage and shipping requirements? ☐ Yes ☐ No
If yes, please provide on page 2.

ADDITIONAL PRODUCT INFORMATION

Is there a minimum order quantity?
If yes, ☐ Case ☐ Carton ☐ Item
Number of Pieces? _____
Shelf Life: 24 Months
Whsl. Code #: _____
Fineline Code: _____
Is Item? ☐ Unit Dose ☐ Unit of Use
If Unit Dose, is item bar coded to unit dose for Hospital tracking purposes?
☐ Yes ☐ No
Will handling data change in the first:
6 months? ☐ Yes
9 months? ☐ Yes
12 months? ☐ Yes
Unknown? ☐ Yes

ITEM AND PACKING INFORMATION

Size/Strength /Form	Unit Of Sale	UPC Code	Mstr. Shpr.	Inner Case Pk	Wght. Lbs.	Cube	Case Dimensions	Item Dimensions	Pallet Dimensions	# Cases/ Pallet
1000 .6mg Tablet	☒ Bottle ☐ Box ☐ Glass jar ☐ Ampule ☐ Other _____	Case:	144	12	Case: 32.45lbs		Depth: 15.50"	Depth: 3.90"	Depth:	30
		Carton:			Carton:		Height: 12.00"	Height: 3.90"	Height:	
		Item: 305910944100			Item: 0.21 lbs		Width: 12.00"	Width: 1.90"	Width:	

For Generic Drug Products: I. Orange Book Rating: _____ II. Product Color: White
III. Brand Name Equivalent: _____ IV. Generic Name For Brand: _____

COST INFORMATION

	Regular Cost ($)		Purchase Allowance ☐ OI ☐ BB $	Purchase Allowance ☐ OI ☐ BB %	Distribution Allowance ☐ OI ☐ BB $	Distribution Allowance ☐ OI ☐ BB %	Invoice Cost ($)	Net Cost ($)	Mfr's AWP	Avg Retl Price ($)	SRP ($)	Excise Tax
DZ												
EA	$69.50								$174.99			
PPK												

This offer is made on a proportionally equal basis to all sellers' accounts completive with customer. Signature: _____

Revised 02/21/06

HDMA Standard Product Information **Pharmaceutical Products**

Item Description: Colchicine .6mg Tablets 1000 **Manufacturer:** Watson Pharmaceuticals, Inc.

If additional information is necessary, provide on right of page or as attachment.

HAZARDOUS MATERIAL INFORMATION

Is this product:

a) Cytotoxic? ☐ Yes ☒ No
b) Carcinogen? ☐ Yes ☒ No
c) Inhalation Hazard? ☐ Yes ☒ No
d) Contact Hazard? ☐ Yes ☒ No

Is this item considered a carcinogen? ☐ Yes ☒ No

Is this item an aerosol requiring special storage? ☐ Yes ☒ No

Does this product require special clean-up instructions? ☐ Yes ☒ No

If yes, attach MSDS with special instructions.

Department of Transportation (DOT) I.D. Number: _____

Hazard Class/ORM Code: _____

OSHA/DOT CHEMICAL STORAGE CLASS

Please check appropriate Class(s) for this product.

☐ ORGANIC ☐ ANTINEOPLASTIC
☐ INORGANIC ☐ STEROID/ANDROGEN
☐ CORROSIVE/OXIDIZER ☐ ESSENTIAL CHEMICAL
☐ AEROSOL ☐ PRECURSOR CHEMICAL (Describe below)
☐ AEROSOL CLASS ☐ MAXIMUM QTY LEVEL

Is the product restricted for air shipping?

☐ Passenger
☐ Cargo
☐ Passenger & Cargo

Precursor Chemical:			Size/Strength
Ephedrine	☐ Yes	☐ No	_____
Pseudoephedrine	☐ Yes	☐ No	_____
Phenylpropanolamine	☐ Yes	☐ No	_____

ADDITIONAL STORAGE AND SHIPPING REQUIREMENTS

Is this product to be shipped to customers on ice? ☐ Yes ☐ No

Is this product to be shipped to customers on dry ice? ☐ Yes ☐ No

Does this product require refrigerated truck for transport? ☐ Yes ☐ No

Is this Product State Regulated? ☐ Yes ☐ No

If yes, list states on the right or as an attachment.

Are there special returns requirements? ☐ Yes ☐ No

If yes, provide requirements in the space to the right or as attachment.

ADDITIONAL INFORMATION AS NECESSARY

HDMA Standard Product Information Form — Pharmaceutical Products

Date: _____ Page 1 of 2

PRODUCT INFORMATION

Manufacturer/Broker Name: Watson Laboratories Number: _____
Product Name: Colchicine Tablets
Product ID Number: _____
☒ NDC 00591-0944-01 ☒ UPC/GTIN # 3-0591094401-8
Description: Colchicine .6mg Tablets 100
Address: _____
City, State, Zip: _____
Key Contact: Vince Rinaudo Fax: 318-868-8927
Phone Number: 318-868-9126 Ext: _____
Phone Number: _____ Ext: _____
Is the Product? ☐ Direct Ship Item ☐ Drop Ship Item
Is the Product a Controlled Drug? ☐ Yes ☒ No
If Yes, Schedule Number: _____
Is this ARCOS reportable? ☐ Yes ☒ No
Is this Product a Legend Device? ☐ Yes ☒ No
Country of Origin: USA
Harmonization Code Number for International Shipping: _____
Is this product a Hazardous Material or Cytotoxic Agent?
☐ Yes ☒ No If yes, provide additional information on page 2.
Attach copy of Material Safety Data Sheet (MSDS)
Attach Package Insert

SPECIAL HANDLING AND STORAGE REQUIREMENTS

a. Temperature – Indicate the normal temperature range for this product.

I.	Controlled Room Temperature (68° – 77° F)	☐
II.	Room Temperature (59° – 86° F)	☒
III.	Excessive Heat (>104° F)	☐
IV.	Cool (46° – 59° F)	☐
V.	Refrigerated (36° – 46° F)	☐
VI.	Frozen (-4° – 14° F)	☐
VII.	No Requirement	☐

b. Are temperature excursions permitted/allowed for product? ☐ Yes ☐ No
If Yes, provide the temperature range and hours duration:
_____ and _____

c. Are there additional storage and shipping requirements? ☐ Yes ☐ No
If yes, please provide on page 2.

10

ADDITIONAL PRODUCT INFORMATION

Is there a minimum order quantity?
If yes, ☐ Case ☐ Carton ☐ Item
Number of Pieces? _____
Shelf Life: 24 Months
Whsl. Code #: _____
Fineline Code: _____
Is Item? ☐ Unit Dose ☐ Unit of Use
If Unit Dose, is item bar coded to unit dose for Hospital tracking purposes?
☐ Yes ☐ No
Will handling data change in the first:
6 months? ☐ Yes
9 months? ☐ Yes
12 months? ☐ Yes
Unknown? ☐ Yes

ITEM AND PACKING INFORMATION

Size/Strength /Form	Unit Of Sale	UPC Code	Mstr. Shpr.	Inner Case Pk	Wght. Lbs.	Cube	Case Dimensions	Item Dimensions	Pallet Dimensions	# Cases/ Pallet
100 .6mg Tablet	☒ Bottle ☐ Box ☐ Glass Jar ☐ Ampule ☐ Other	Case:	144	12	Case: 8.09 lbs		Depth: 12.50"	Depth: 3.40"	Depth:	60
		Carton:			Carton:		Height: 10.75"	Height: 3.40"	Height:	
		Item: 305910944018			Item: 0.05 lbs		Width: 9.75"	Width: 1.50"	Width:	

For Generic Drug Products: I. Orange Book Rating: _____ II. Product Color: White
III. Brand Name Equivalent: _____ IV. Generic Name For Brand: _____

COST INFORMATION

	Regular Cost ($)	Purchase Allowance ☐ OI ☐ BB $	Purchase Allowance %	Distribution Allowance ☐ OI ☐ BB $	Distribution Allowance %	Invoice Cost ($)	Net Cost ($)	Mfr's AWP	Avg Retl Price ($)	$RP ($)	Excise Tax
DZ											
EA	$9.00							$24.96			
PPK											

This offer is made on a proportionally equal basis to all sellers' accounts completive with customer. Signature: _____

Revised 02/21/06

HDMA Standard Product Information **Pharmaceutical Products**

Item Description: Colchicine .6mg Tablets 100 **Manufacturer:** Watson Pharmaceuticals, Inc.

If additional information is necessary, provide on right of page or as attachment.

HAZARDOUS MATERIAL INFORMATION

Is this product:

a) Cytotoxic?	☐ Yes	☒ No
b) Carcinogen?	☐ Yes	☒ No
c) Inhalation Hazard?	☐ Yes	☒ No
d) Contact Hazard?	☐ Yes	☒ No

Is this item considered a carcinogen? ☐ Yes ☒ No

Is this item an aerosol requiring special storage? ☐ Yes ☒ No

Does this product require special clean-up instructions? ☐ Yes ☒ No

If yes, attach MSDS with special instructions.

Department of Transportation (DOT) I.D. Number: _____

Hazard Class/ORM Code: _____

OSHA/DOT CHEMICAL STORAGE CLASS

Please check appropriate Class(s) for this product.

☐ ORGANIC	☐ ANTINEOPLASTIC
☐ INORGANIC	☐ STEROID/ANDROGEN
☐ CORROSIVE/OXIDIZER	☐ ESSENTIAL CHEMICAL
☐ AEROSOL	☐ PRECURSOR CHEMICAL (Describe below)
☐ AEROSOL CLASS	☐ MAXIMUM QTY LEVEL

Is the product restricted for air shipping?

☐ Passenger
☐ Cargo
☐ Passenger & Cargo

Precursor Chemical:			Size/Strength
Ephedrine	☐ Yes	☐ No	_____
Pseudoephedrine	☐ Yes	☐ No	_____
Phenylpropanolamine	☐ Yes	☐ No	_____

ADDITIONAL STORAGE AND SHIPPING REQUIREMENTS

Is this product to be shipped to customers on ice?	☐ Yes	☐ No
Is this product to be shipped to customers on dry ice?	☐ Yes	☐ No
Does this product require refrigerated truck for transport?	☐ Yes	☐ No
Is this Product State Regulated?	☐ Yes	☐ No

If yes, list states on the right or as an attachment.

Are there special returns requirements? ☐ Yes ☐ No

If yes, provide requirements in the space to the right or as attachment.

ADDITIONAL INFORMATION AS NECESSARY

11

Date: _____ Page 1 of 2

PRODUCT INFORMATION

Manufacturer/Broker Name: Watson Laboratories Number: _____
Product Name: Colchicine Tablets
Product ID Number: _____
☒ NDC 00591-0944-10 ☒ UPC/GTIN # 3-0591094410-0
Description: Colchicine .6mg Tablets 1000
Address: _____
City, State, Zip: _____
Key Contact: Vince Rinaudo Fax: 318-868-8927
Phone Number: 318-868-9126 Ext: _____
Phone Number: _____ Ext: _____
Is the Product? ☐ Direct Ship Item ☐ Drop Ship Item
Is the Product a Controlled Drug? ☐ Yes ☒ No
If Yes, Schedule Number: _____
Is this ARCOS reportable? ☐ Yes ☒ No
Is this Product a Legend Device? ☐ Yes ☒ No
Country of Origin: USA
Harmonization Code Number for International Shipping: _____
Is this product a Hazardous Material or Cytotoxic Agent?
☐ Yes ☒ No If yes, provide additional information on page 2.
Attach copy of Material Safety Data Sheet (MSDS)
Attach Package Insert

SPECIAL HANDLING AND STORAGE REQUIREMENTS

a. Temperature – Indicate the normal temperature range for this product.

I.	Controlled Room Temperature (68° – 77° F)	☐
II.	Room Temperature (59° – 86° F)	☒
III.	Excessive Heat (>104° F)	☐
IV.	Cool (46° – 59° F)	☐
V.	Refrigerated (36° – 46° F)	☐
VI.	Frozen (-4° – 14° F)	☐
VII.	No Requirement	☐

b. Are temperature excursions permitted/allowed for product? ☐ Yes ☐ No
If Yes, provide the temperature range and hours duration:
_____ and _____

c. Are there additional storage and shipping requirements? ☐ Yes ☐ No
If yes, please provide on page 2.

ADDITIONAL PRODUCT INFORMATION

Is there a minimum order quantity?
If yes, ☐ Case ☐ Carton ☐ Item
Number of Pieces? _____
Shelf Life: 24 Months
Whsl. Code #: _____
Fineline Code: _____
Is Item? ☐ Unit Dose ☐ Unit of Use
If Unit Dose, is item bar coded to unit dose for Hospital tracking purposes?
☐ Yes ☐ No
Will handling data change in the first:
6 months? ☐ Yes
9 months? ☐ Yes
12 months? ☐ Yes
Unknown? ☐ Yes

ITEM AND PACKING INFORMATION

Size/Strength /Form	Unit Of Sale	UPC Code	Mstr. Shpr.	Inner Case Pk	Wght. Lbs.	Cube	Case Dimensions	Item Dimensions	Pallet Dimensions	# Cases/ Pallet
1000 .6mg Tablet	☒ Bottle ☐ Box ☐ Glass jar ☐ Ampule ☐ Other	Case:	144	12	Case: 32.45lbs		Depth: 15.50"	Depth: 3.90"	Depth:	30
		Carton:			Carton:		Height: 12.00"	Height: 3.90"	Height:	
		Item: 305910944100			Item: 0.21 lbs		Width: 12.00"	Width: 1.90"	Width:	

For Generic Drug Products: I. Orange Book Rating: _____ II. Product Color: White
III. Brand Name Equivalent: _____ IV. Generic Name For Brand: _____

COST INFORMATION

	Regular Cost ($)		Purchase Allowance ☐ OI ☐ BB $	Purchase Allowance ☐ OI ☐ BB %	Distribution Allowance ☐ OI ☐ BB $	Distribution Allowance ☐ OI ☐ BB %	Invoice Cost ($)	Net Cost ($)	Mfr's AWP	Avg Retl Price ($)	SRP ($)	Excise Tax
DZ												
EA	$69.50								$174.99			
PPK												

This offer is made on a proportionally equal basis to all sellers' accounts completive with customer. Signature: _____

Revised 02/21/06

HDMA Standard Product Information **Pharmaceutical Products**

Item Description: Colchicine .6mg Tablets 1000 **Manufacturer:** Watson Pharmaceuticals, Inc.

If additional information is necessary, provide on right of page or as attachment.

HAZARDOUS MATERIAL INFORMATION	ADDITIONAL INFORMATION AS NECESSARY

Is this product:

a) Cytotoxic? ☐ Yes ☒ No
b) Carcinogen? ☐ Yes ☒ No
c) Inhalation Hazard? ☐ Yes ☒ No
d) Contact Hazard? ☐ Yes ☒ No

Is this item considered a carcinogen? ☐ Yes ☒ No

Is this item an aerosol requiring special storage? ☐ Yes ☒ No

Does this product require special clean-up instructions? ☐ Yes ☒ No

If yes, attach MSDS with special instructions.

Department of Transportation (DOT) I.D. Number: _____

Hazard Class/ORM Code: _____

OSHA/DOT CHEMICAL STORAGE CLASS

Please check appropriate Class(s) for this product.

☐ ORGANIC ☐ ANTINEOPLASTIC
☐ INORGANIC ☐ STEROID/ANDROGEN
☐ CORROSIVE/OXIDIZER ☐ ESSENTIAL CHEMICAL
☐ AEROSOL ☐ PRECURSOR CHEMICAL (Describe below)
☐ AEROSOL CLASS ☐ MAXIMUM QTY LEVEL

Is the product restricted for air shipping?

☐ Passenger
☐ Cargo
☐ Passenger & Cargo

Precursor Chemical:			Size/Strength
Ephedrine	☐ Yes	☐ No	_____
Pseudoephedrine	☐ Yes	☐ No	_____
Phenylpropanolamine	☐ Yes	☐ No	_____

ADDITIONAL STORAGE AND SHIPPING REQUIREMENTS

Is this product to be shipped to customers on ice? ☐ Yes ☐ No

Is this product to be shipped to customers on dry ice? ☐ Yes ☐ No

Does this product require refrigerated truck for transport? ☐ Yes ☐ No

Is this Product State Regulated? ☐ Yes ☐ No

If yes, list states on the right or as an attachment.

Are there special returns requirements? ☐ Yes ☐ No

If yes, provide requirements in the space to the right or as attachment.

Revised 02/21/06

13

PRODUCT INFORMATION

Manufacturer/Broker Name: Watson Laboratories Number: _____
Product Name: Colchicine Tablets
Product ID Number: _____
☒ NDC 00591-0944-01 ☒ UPC/GTIN # 3-0591094401-8
Description: Colchicine .6mg Tablets 100
Address: _____
City, State, Zip: _____
Key Contact: Gary Salter Fax: 850-235-1710
Phone Number: 850-235-1765 Ext: _____
Phone Number: _____ Ext: _____
Is the Product? ☐ Direct Ship Item ☐ Drop Ship Item
Is the Product a Controlled Drug? ☐ Yes ☒ No
If Yes, Schedule Number: _____
Is this ARCOS reportable? ☐ Yes ☒ No
Is this Product a Legend Device? ☐ Yes ☒ No
Country of Origin: USA
Harmonization Code Number for International Shipping: _____
Is this product a Hazardous Material or Cytotoxic Agent?
☐ Yes ☒ No If yes, provide additional information on page 2.
Attach copy of Material Safety Data Sheet (MSDS)
Attach Package Insert

SPECIAL HANDLING AND STORAGE REQUIREMENTS

a. Temperature – Indicate the normal temperature range for this product.

I.	Controlled Room Temperature (68° – 77° F)	☐
II.	Room Temperature (59° – 86° F)	☒
III.	Excessive Heat (>104° F)	☐
IV.	Cool (46° – 59° F)	☐
V.	Refrigerated (36° – 46° F)	☐
VI.	Frozen (-4° – 14° F)	☐
VII.	No Requirement	☐

b. Are temperature excursions permitted/allowed for product? ☐ Yes ☐ No
If Yes, provide the temperature range and hours duration:
_____ and _____

c. Are there additional storage and shipping requirements? ☐ Yes ☐ No
If yes, please provide on page 2.

ADDITIONAL PRODUCT INFORMATION

Is there a minimum order quantity?
If yes, ☐ Case ☐ Carton ☐ Item
Number of Pieces? _____
Shelf Life: 24 Months
Whsl. Code #: _____
Fineline Code: _____
Is Item? ☐ Unit Dose ☐ Unit of Use
If Unit Dose, is item bar coded to unit dose for Hospital tracking purposes?
☐ Yes ☐ No
Will handling data change in the first:
6 months? ☐ Yes
9 months? ☐ Yes
12 months? ☐ Yes
Unknown? ☐ Yes

ITEM AND PACKING INFORMATION

Size/Strength /Form	Unit Of Sale	UPC Code	Mstr. Shpr.	Inner Case Pk	Wght. Lbs.	Cube	Case Dimensions	Item Dimensions	Pallet Dimensions	# Cases/ Pallet
100 .6mg Tablet	☒ Bottle ☐ Box ☐ Glass jar ☐ Ampule ☐ Other	Case:	144	12	Case: 8.09 lbs		Depth: 12.50"	Depth: 3.40"	Depth:	60
		Carton:			Carton:		Height: 10.75"	Height: 3.40"	Height:	
		Item: 305910944018			Item: 0.05 lbs		Width: 9.75"	Width: 1.50"	Width:	

For Generic Drug Products: I. Orange Book Rating: _____ II. Product Color: White
III. Brand Name Equivalent: _____ IV. Generic Name For Brand: _____

COST INFORMATION

	Regular Cost ($)		Purchase Allowance ☐ OI ☐ BB $	Purchase Allowance %	Distribution Allowance ☐ OI ☐ BB $	Distribution Allowance %	Invoice Cost ($)	Net Cost ($)	Mfr's AWP	Avg Retl Price ($)	SRP ($)	Excise Tax
DZ												
EA	$9.00								$24.95			
PPK												

This offer is made on a proportionally equal basis to all sellers' accounts competitive with customer. Signature: _____

Revised 02/21/06

HDMA Standard Product Information **Pharmaceutical Products**

Item Description: Colchicine .6mg Tablets 100 Manufacturer: Watson Pharmaceuticals, Inc.

If additional information is necessary, provide on right of page or as attachment.

HAZARDOUS MATERIAL INFORMATION

Is this product:

a) Cytotoxic?	☐ Yes	☒ No
b) Carcinogen?	☐ Yes	☒ No
c) Inhalation Hazard?	☐ Yes	☒ No
d) Contact Hazard?	☐ Yes	☒ No

Is this item considered a carcinogen? ☐ Yes ☒ No

Is this item an aerosol requiring special storage? ☐ Yes ☒ No

Does this product require special clean-up instructions? ☐ Yes ☒ No

If yes, attach MSDS with special instructions.

Department of Transportation (DOT) I.D. Number: _____

Hazard Class/ORM Code: _____

OSHA/DOT CHEMICAL STORAGE CLASS

Please check appropriate Class(s) for this product.

☐ ORGANIC	☐ ANTINEOPLASTIC
☐ INORGANIC	☐ STEROID/ANDROGEN
☐ CORROSIVE/OXIDIZER	☐ ESSENTIAL CHEMICAL
☐ AEROSOL	☐ PRECURSOR CHEMICAL (Describe below)
☐ AEROSOL CLASS	☐ MAXIMUM QTY LEVEL

Is the product restricted for air shipping?

☐ Passenger
☐ Cargo
☐ Passenger & Cargo

Precursor Chemical:			Size/Strength
Ephedrine	☐ Yes	☐ No	_____
Pseudoephedrine	☐ Yes	☐ No	_____
Phenylpropanolamine	☐ Yes	☐ No	_____

ADDITIONAL STORAGE AND SHIPPING REQUIREMENTS

Is this product to be shipped to customers on ice?	☐ Yes	☐ No
Is this product to be shipped to customers on dry ice?	☐ Yes	☐ No
Does this product require refrigerated truck for transport?	☐ Yes	☐ No
Is this Product State Regulated?	☐ Yes	☐ No

If yes, list states on the right or as an attachment.

Are there special returns requirements? ☐ Yes ☐ No

If yes, provide requirements in the space to the right or as attachment.

ADDITIONAL INFORMATION AS NECESSARY

Revised 02/21/06

15

HDMA Standard Product Information — Pharmaceutical Products — ☐ New Item ☐ Promotional Deal ☐ Open Stock ☐ Post Launch Change

Date: _____

PRODUCT INFORMATION

Manufacturer/Broker Name: Watson Laboratories Number: _____

Product Name: Colchicine Tablets

Product ID Number: _____

☒ NDC 00591-0944-10 ☒ UPC/GTIN # 3-0591094410-0

Description: Colchicine .6mg Tablets 1000

Address: _____

City, State, Zip: _____

Key Contact: Gary Salter Fax: 850-235-1710

Phone Number: 850-235-1765 Ext: _____

Phone Number: _____ Ext: _____

Is the Product? ☐ Direct Ship Item ☐ Drop Ship Item

Is the Product a Controlled Drug? ☐ Yes ☒ No

If Yes, Schedule Number: _____

Is this ARCOS reportable? ☐ Yes ☒ No

Is this Product a Legend Device? ☐ Yes ☒ No

Country of Origin: USA

Harmonization Code Number for International Shipping: _____

Is this product a Hazardous Material or Cytotoxic Agent?

☐ Yes ☒ No If yes, provide additional information on page 2.

Attach copy of Material Safety Data Sheet (MSDS)

Attach Package Insert

SPECIAL HANDLING AND STORAGE REQUIREMENTS

a. Temperature – Indicate the normal temperature range for this product.

I.	Controlled Room Temperature (68° – 77° F)	☐
II.	Room Temperature (59° – 86° F)	☒
III.	Excessive Heat (>104° F)	☐
IV.	Cool (46° – 59° F)	☐
V.	Refrigerated (36° – 46° F)	☐
VI.	Frozen (-4° – 14° F)	☐
VII.	No Requirement	☐

b. Are temperature excursions permitted/allowed for product? ☐ Yes ☐ No

If Yes, provide the temperature range and hours duration:

_____ and _____

c. Are there additional storage and shipping requirements? ☐ Yes ☐ No

If yes, please provide on page 2.

ADDITIONAL PRODUCT INFORMATION

Is there a minimum order quantity?

If yes, ☐ Case ☐ Carton ☐ Item

Number of Pieces? _____

Shelf Life: 24 Months

Whsl. Code #: _____

Fineline Code: _____

Is Item? ☐ Unit Dose ☐ Unit of Use

If Unit Dose, is item bar coded to unit dose for Hospital tracking purposes?

☐ Yes ☐ No

Will handling data change in the first:

6 months? ☐ Yes

9 months? ☐ Yes

12 months? ☐ Yes

Unknown? ☐ Yes

ITEM AND PACKING INFORMATION

Size/Strength /Form	Unit Of Sale	UPC Code	Mstr. Shpr.	Inner Case Pk	Wght. Lbs.	Cube	Case Dimensions	Item Dimensions	Pallet Dimensions	# Cases/ Pallet
1000 .6mg Tablet	☒ Bottle ☐ Box ☐ Glass Jar ☐ Ampule ☐ Other	Case:	144	12	Case: 32.46lbs		Depth: 15.50"	Depth: 3.90"	Depth:	30
		Carton:			Carton:		Height: 12.00"	Height: 3.90"	Height:	
		Item: 305910944100			Item: 0.21 lbs		Width: 12.00"	Width: 1.90"	Width:	

For Generic Drug Products: I. Orange Book Rating: _____ II. Product Color: White

III. Brand Name Equivalent: _____ IV. Generic Name For Brand: _____

COST INFORMATION

	Regular Cost ($)		Purchase Allowance ☐ OI ☐ BB $	Purchase Allowance %	Distribution Allowance ☐ OI ☐ BB $	Distribution Allowance %	Invoice Cost ($)	Net Cost ($)	Mfr's AWP	Avg Retl Price ($)	SRP ($)	Excise Tax
DZ												
EA		$69.50							$174.99			
PPK												

This offer is made on a proportionally equal basis to all sellers' accounts competitive with customer. Signature: _____

Revised 02/21/06

16

HDMA Standard Product Information **Pharmaceutical Products**

Item Description: Colchicine .6mg Tablets 1000 **Manufacturer:** Watson Pharmaceuticals, Inc.

If additional information is necessary, provide on right of page or as attachment.

HAZARDOUS MATERIAL INFORMATION

Is this product:

- a) Cytotoxic? ☐ Yes ☒ No
- b) Carcinogen? ☐ Yes ☒ No
- c) Inhalation Hazard? ☐ Yes ☒ No
- d) Contact Hazard? ☐ Yes ☒ No

Is this item considered a carcinogen? ☐ Yes ☒ No

Is this item an aerosol requiring special storage? ☐ Yes ☒ No

Does this product require special clean-up instructions? ☐ Yes ☒ No

If yes, attach MSDS with special instructions.

Department of Transportation (DOT) I.D. Number: _____

Hazard Class/ORM Code: _____

OSHA/DOT CHEMICAL STORAGE CLASS

Please check appropriate Class(s) for this product.

☐ ORGANIC	☐ ANTINEOPLASTIC
☐ INORGANIC	☐ STEROID/ANDROGEN
☐ CORROSIVE/OXIDIZER	☐ ESSENTIAL CHEMICAL
☐ AEROSOL	☐ PRECURSOR CHEMICAL (Describe below)
☐ AEROSOL CLASS	☐ MAXIMUM QTY LEVEL

Is the product restricted for air shipping?

- ☐ Passenger
- ☐ Cargo
- ☐ Passenger & Cargo

Precursor Chemical:			Size/Strength
Ephedrine	☐ Yes	☐ No	_____
Pseudoephedrine	☐ Yes	☐ No	_____
Phenylpropanolamine	☐ Yes	☐ No	_____

ADDITIONAL STORAGE AND SHIPPING REQUIREMENTS

Is this product to be shipped to customers on ice?	☐ Yes	☐ No
Is this product to be shipped to customers on dry ice?	☐ Yes	☐ No
Does this product require refrigerated truck for transport?	☐ Yes	☐ No
Is this Product State Regulated?	☐ Yes	☐ No

If yes, list states on the right or as an attachment.

Are there special returns requirements? ☐ Yes ☐ No

If yes, provide requirements in the space to the right or as attachment.

ADDITIONAL INFORMATION AS NECESSARY

17

Revised 02/21/06